

CURRICULUM VITAE

Steven L. Mansberger, M.D., M.P.H.

Chenoweth Chair and Chief, Legacy Devers Eye Institute
Director of Glaucoma Services and Fellowship Program, Legacy Devers Eye Institute
Clinical Vice-President and Senior Scientist, Legacy Health
Affiliate Professor of Ophthalmology, Casey Eye Institute at OHSU
Clinical Professor, Dept of Public Health and Preventive Medicine at OHSU
Past President, Board of Directors, Oregon Academy of Ophthalmology

Devers Eye Institute at Legacy Health
1040 NW 22nd Ave, Suite 200
Portland, OR 97210
Phone: 503-413-8202
smansberger@deverseye.org

Education

July 1987-May 1991	Miami University of Ohio, Oxford, OH. B.A, Zoology
July 1991-May 1995	Indiana University School of Medicine; Indianapolis, IN. Doctor of Medicine
September 2000-June 2002	Oregon Health Science University (OHSU) Portland, OR Masters of Public Health (MPH) (Biostatistics/Epidemiology)
June 2004-2005	Oregon Health Science University Human Investigations Program (Clinical Research track)

Professional Experience

July 1995-June 1996	Internal Medicine , St. Vincent Hospital, Portland, Oregon.
July 1996-June 1999	Ophthalmology residency , Shiley Eye Center, University of California, San Diego.
July 1999-June 2000	Glaucoma Fellowship , Devers Eye Institute, Good Samaritan Hospital. Portland, OR.
July 2000-2006	Assistant Scientist Devers Eye Institute/Legacy Health System, Portland, OR
July 2000-Present	Head of Ophthalmic Clinical Trials , Devers Eye Institute/Legacy Health System, Portland, OR
July 2000-2008	Adjunct Assistant Professor of Ophthalmology , Oregon Health Science University, Portland, OR
July 2000-2009	Director Glaucoma Service , Veteran's Hospital, Portland, OR
June 2002-July 2004	Medical Director , Devers Memorial Eye Clinic, Portland, OR

January 2004-2008	Clinical Assistant Professor of Public Health and Preventive Medicine , Oregon Health Science University
November 2006-2012	Associate Scientist , Legacy Health System
November 2008-Present	Affiliate Associate Professor of Public Health and Preventive Medicine , Oregon Health Science University
June 2009-2012	Co-Medical Director , Telemedicine Services, Legacy Health System
July 2009-Present	Director of Glaucoma Services , Devers Eye Institute
July 2009-Present	Director of Glaucoma Fellowship , Devers Eye Institute
March 2012-Present	Senior Scientist , Legacy Health
September 2012-July 2019	Vice-Chair and Head of Clinical Operations . Legacy Devers Eye Institute
February 2014-Present	Affiliate Professor of Ophthalmology , Oregon Health Science University.
2010- Present	Co-Director , Clinical Trials Research and Biostatistics (CTRB) center
July 2019-Present	Chenoweth Chair and Chief of Ophthalmology , Legacy Devers Eye Institute

Research Background:

Wilmer Eye Institute, Eye Pathology Laboratory; Johns Hopkins University, Baltimore, Maryland, October 1994-November 1994.

-Pathologic examination of ocular specimens
Research Director: W. Richard Green, M.D.

Indiana University Glaucoma Research and Diagnostic Lab; Indianapolis, Indiana, May 1992-June 1995.

-Examining blood flow using the Scanning Laser Ophthalmoscope, Blue Field Simulator, and Color Doppler Imaging
Research Director: Alon Harris, Ph.D.

Devers Eye Institute, Portland, Oregon, January 1994-February 1994.

-Investigating retrobulbar vessel anatomy using plastic dye casting and electron microscopy
Research Director: George A. Cioffi, M.D.

Glaucoma Center and Research Laboratories, University of California, San Diego; San Diego, CA. January 1997-June 1999

-Functional testing of glaucoma including achromatic automated perimetry and short wavelength perimetry.
-Structural analysis of the optic nerve with confocal scanning laser ophthalmoscopy

-Circadian rhythm of intraocular pressure in the young and elderly subjects
Research Director: Robert N. Weinreb, M.D., John Liu, PhD

Devers Eye Institute/Discoveries in Sight; Portland, OR. July 1999-present

-Functional testing of glaucoma including achromatic automated perimetry and frequency doubling technology perimetry.

-Structural analysis of the optic nerve with confocal scanning laser ophthalmoscopy

-Community screening of glaucoma with frequency doubling technology perimetry

-Prevalence of eye diseases in American Indian/Alaskan Natives

-Predictive ability of nonmydriatic imaging for diabetic retinopathy

Research Directors: George A. Cioffi, M.D., Chris A. Johnson, PhD

Honors and Awards

1. Mid-American Conference, All-Academic team-Soccer, 3rd team 1987
2. Mid-American Conference, All-Academic team-Soccer, 2nd team 1988.
3. Cum Laude, Miami University of Ohio, May 1991.
4. Poster Presentation, Third place, Indiana State Medical Association, Indianapolis, IN, 1994.
5. Poster presentation, Third Place, Midwest Student Research Forum, Omaha, NE, 1994.
6. Roche Laboratories Travel Award, National Student Research Forum, Galveston, TX, 1994.
7. Chief Resident, July 1998-June 1999.
8. Outstanding Resident Award, June 1999.
9. Resident Knowledge Award, June 1999.
10. Heed Ophthalmic Foundation Fellowship, July 1999-June 2000.
11. Master's Thesis of the Year Nomination, June 2002
12. The Robert Watzke Ophthalmology Instructor of the Year, Casey Eye Institute, Oregon Health Science University, June 2002
13. American Glaucoma Society Research Fellowship in Glaucoma, March 2003
14. American Glaucoma Society Research Fellowship in Glaucoma, March 2004
15. Scientist of the Month, Legacy Health System, June 2004
16. ASCI/AAP travel award, April 2006
17. Achievement Award, American Academy of Ophthalmology, October 2006
18. Leadership Program, American Academy of Ophthalmology, 2006
19. Best Doctors in America: 2007
20. Best Doctors in America: 2008
21. Best Doctors in America: 2009
22. Distinguished Alumni Lecturer, Shiley Eye Center, University of California, San Diego. San Diego, CA. 2010
23. Best Doctors in America: 2010
24. Carmel High School Hall of Fame, Carmel, IN. 2010
25. Best Doctors in America: 2011
26. 3rd Place Poster, Diabetes Translational Research Conference, Minneapolis, MN. 2011
27. Best of the American Glaucoma Society Annual Meeting, Presented at the World Glaucoma Association meeting, Paris, France. 2011.
28. Best Anterior Segment research presentation, American Academy of Ophthalmology, October 2011.
29. Best Doctors in America, 2012
30. Portland's Best Doctors, 2013
31. International Glaucoma Review, Editor's choice, 2013. "Reduction in Intraocular pressure after Cataract Surgery: The Ocular Hypertension Treatment Study"
32. American Ophthalmological Society (AOS), accepted May 2013 and initiated 5/2014
33. American Academy of Ophthalmology, State Society Award. November 2013. "Free glaucoma screenings with your legislator".

34. Best Doctors in America, 2014
35. Senior Achievement Award, American Academy of Ophthalmology, 2014
36. President's Award, Optometric Glaucoma Society, 2014
37. Cole Eye Institute Distinguished Research Lecturer, Cleveland Clinic. 2014
38. International Scholar Lecture, Canadian Glaucoma Society, April 2016
39. Distinguished Ophthalmology Alumni Sponsored Lecturer, University of Alabama. 2016
40. Best Doctors in America, 2016
41. Castle Connolly Top Doctors in America, 2017
42. Best Doctors in America, 2017
43. Castle Connolly Top Doctors in America, 2018
44. Best Doctors in America, 2018
45. Best Doctors in America, 2019
46. Castle Connolly Top Doctors in America, 2019
47. Best Doctors in America, 2021
48. Castle Connolly Top Doctors in America, 2021
49. Best Doctors in America, 2022
50. Castle Connolly Top Doctors in America, 2022
51. Wistar Morris Award-for contributions to the Good Samaritan Foundation, 2023
52. Best Doctors in America, 2023
53. Castle Connolly Top Doctors in America, 2023

Professional Organizations

- Heed Ophthalmology Foundation
 - Member 2000-present
- American Glaucoma Society
 - Provisional Member 2000-2005
 - Active Member 2005-present
- The Association for Research in Vision and Ophthalmology (ARVO),
 - 1993-present
- American Academy of Ophthalmology
 - Member 1998- present,
 - Active Fellow 2001-present
- Oregon Academy of Ophthalmology
 - 1999-present
- World Glaucoma Association
 - 2005-present
- American Society of Cataract and Refractive Surgery,
 - Member 1997- 2002
- Eye Care America
 - 2000-present
- Pan American Academy of Ophthalmology
 - 2003-2007
- American Ophthalmology Society
 - Member 2013- present

Committee Membership/Leadership Positions

- Legacy Health System
 - Legacy Telemedicine Program
 - Co-medical director 2009-2012
 - Steering Committee 2009-2016

- Continuing Medical Education Committee
 - Chair, 2011- 2018
 - Member, 2008-2018
- Devers Eye Institute Executive Committee
 - Member 2008-present
- Good Samaritan Surgical Services Steering Committee
 - Member, 2007-2016
- Transitional Care Committee-
 - Member, June 2002-July 2004
- Block Time Committee
 - Member, 2004-2019
- Ophthalmology Surgery Committee
 - Member, 2000-2008
- Graduate Medical Education Committee
 - Member, 2008-2014
- Legacy Leadership Program
 - Member, 2012-2013
- Legacy Ambulatory Procedure Center Steering Committee
 - Member 2018-present
- Oregon Academy of Ophthalmology
 - Past President, 2014-present
 - President, 2012-2014
 - Vice President, 2010-2012
 - Secretary/Treasurer 2007-2009
 - Board of Directors
 - Member, 2008-present
- American Glaucoma Society
 - Board of Directors
 - Member, 2010-2013, 2024-current
 - Education and Communications Committee
 - Chair 2010-2013: Created new website, new logo, AUPO fellowship committee, Multimedia committee with patient videos
 - AGS Newsletter Editor 2007-2009
 - Member, 2005-2009
 - Nominating Committee
 - Member, 2011-2013
 - Strategic Planning Committee
 - Member 2008-2010
 - Bylaws review task force for the American Glaucoma Society Foundation, 2012
 - Committee on the AGS Foundation, 2013
 - AGS/AAO Subspeciality Day committee, 2023-25
- American Glaucoma Society Foundation
 - Board member 2022-present
- American Academy of Ophthalmology
 - ONE committee-glaucoma
 - Member 2005-2009
 - BCSC Sec. 1: Update on General Medicine – Consultant for Epidemiology
 - 2011-2019
 - Annual Meeting Program Committee – Glaucoma, Scientific reviewer
 - Member, 2012-2016

- Preferred Practice Pattern-Glaucoma Panel – Consultant
 - Member 2014 to present
- EyeNet Editorial Advisory Board
 - Member 2014 to 2021
- Glaucoma Subspecialty Day co-Chair
 - 2023-present
- Ocular Hypertension Treatment Study (OHTS)
 - Executive Committee
 - Member 2007-2013
- World Glaucoma Association
 - Associate Advisory Board
 - Member, 2008-present
 - Poster committee
 - Co-chair-2006-2010
 - Co-chair 2022-23
 - Subcommittee Chair (Clinical Trials, Economics)
 - Co-chair 2008-2010
 - Program Committee 2023
- Oregon Health Science University
 - Resident Selection Committee
 - Member, 2002-2004
- Prevent Blindness America
 - Scientific advisory board committee 2012-2017
- Oregon Medical Association
 - Institutional Continuing Medical Education (CME) Accreditation Committee, 2012-2014
- Glaucoma Research Foundation
 - Scientific Advisory Board, 2013-present
- Good Samaritan Foundation
 - Board of Directors, 2014-2021
- American Board of Ophthalmology
 - Oral Board Examiner, 2007-Present
 - ABO Exam Development committee, 2014-Present. One of 10 glaucoma specialists to develop content for OKAP exams (ophthalmology residents), written exam questions for board licensure, oral exam questions for board licensure, and PORT exams (for maintenance of certification exams for existing ophthalmologists).
 - Committee Chair 2021-2022
 - Committee Chair 2024-present
- Legacy Health Partners
 - Data and Safety Monitoring Committee, 2015-2017
 - Board of Directors, 2021-Present
- AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS) Steering Committee, 2016–2022
- Clarifying the Optimal Application of SLT Therapy (COAST) NIH Study Data Monitoring and Safety Committee, 2021 - Present

Formal Education in Leadership

1. Health Systems Organization, “Delivery of Health Care in America: A systems approach”. Portland State University, 2002
2. Human Investigations Program, “Clinician Scientist Leadership”, Oregon Health Science University, 2004-5

3. American Academy of Ophthalmology Leadership Development Program, 2006-7; nominated by the American Glaucoma Society
4. 'Manager Tools' member, (One-on-One's, feedback, coaching, other manager skills), 2010-current
5. Legacy Physician Leaders training, 2013-2014
6. Leading at Legacy (Lean methodology, coaching) 2015-2019

Board Certification

American Board of Ophthalmology, November 2000, recertification to present

Licensing

California Medical License-April 1997-present

Oregon Medical License-January 2000-present

Executive Editor

1. American Journal of Ophthalmology, Epidemiology section

Editorial Boards of Scientific Journals

1. Journal of Glaucoma, 2006 to present
2. American Journal of Ophthalmology, 2006 to present
3. International Glaucoma Review, 2006 to present

Scientific Journal Review

1. Journal of Glaucoma, 1999 to present
2. Investigative Ophthalmology and Visual Science, 2000 to present
3. JAMA Ophthalmology/Archives of Ophthalmology, 2000 to present
4. British Journal of Ophthalmology, 2000 to present
5. Survey of Ophthalmology, 2000 to present
6. Ophthalmology, 2003-present
7. American Journal of Ophthalmology, 2002-present
8. Current Eye Research, 2004-present
9. Journal of Cataract and Refractive Surgery, 2005-present
10. Optometry and Visual Science, 2006-present
11. Journal of Ophthalmology, 2009-present
12. PLOS, 2013-present

National Institutes of Health (NIH) review

1. October 2016. NIH special emphasis panel (ZRG 1NRCS V08)
2. April 2017. ZEY1 VSN (02).
3. July 2017. ZEY1VSN03
4. March 2018. 2018/05 ZEY1 VSN (01)
5. May 2018. NIH Kidney Nutrition Obesity Diabetes. Mail in reviewer
6. March 2019. NEI Clinical Trials Review
7. Dec 2019. Special Emphasis Panel/Scientific Review Group 2020/05 ZRG1 PSE-H (70)
8. June 2021. Chair. ZEY1 VSN 02 Clinical applications
9. October 2021. ZEY1 VSN (01) NEI Clinical Trial, Large Scale Epidemiology and Secondary Data Analysis Applications
10. April 2022. ZEY1 VSN (01) NEI Clinical Trial and Epidemiology Applications
11. Dec 2022. Co-Chair ZEY1 VSN 02 NEI Secondary Data Analysis Applications Special Emphasis Panel

Corporate Advisory Boards

1. Allergan-Glaucoma. 2005 to 2015
2. Heidelberg Engineering. 2005-2009
3. Genentech- 2010 to 2011
4. Alcon- 2005-2008, 2012-2015
5. Glaukos-2011
6. Merck-2012-2013
7. Sucampo, 2013-2014
8. Valeant Pharmaceuticals, 2013-2014
9. Liquidia Technologies, 2013-2014
10. Forsight Vision5, 2014
11. New World Medical 2014-2016
12. Welch-Allyn, 2014-2016
13. Glaukos, 2016-2017
14. Aerie, 2016-2018
15. Gore, 2016-2018
16. Envisia, 2014-present
 - a. Lead Investigator 2016-2017
 - b. Medical Monitor, ENV515-3-2 study, 2015 – 2019
17. Santen-Glaucoma. 2006-2017
18. Gehrson-Lehmann-2003 to 2018
19. Bausch & Lomb 2013-2017
20. Nicox, 2018-present
 - a. Lead Investigator, 2018-2020
 - b. Stock
21. Thea Pharmaceuticals, 2020-present
22. Kali Care, Inc
 - a. Consultant, 2020- 2022
 - b. Stock
23. ONL Therapeutics, Inc, 2022-present
24. Perfuse Therapeutics, 2022-present
25. Biorasi, 2022
26. Tabia, 2023-present

Copyrights/Patents/Licensing:

1. Copyright: Devers ocular hypertension to glaucoma risk calculator, 2005
2. Copyright: Glaucoma Treatment Compliance Assessment Tool (GTCAT), 2012
3. Copyright: Compliance with Annual Diabetic Eye Exams (CADEES) questionnaire, 2014
4. Patent: Universal Eye drop Cap, 2015. Provisional Patent #62110498
5. Patent: US Patent #11,045,349 B2, Date: June 29,2021. DEVICE FOR MEASURING AND IMPROVING ADHERENCE OF EYE DROPS, PCT App. No. PCT/US2016/015600; US Provisional App. No. 62/110,498
6. Licensing:
 - a. Kali Care. 2020 Glaucoma Treatment Compliance Assessment Tool (GTCAT)-short.
 - b. Tabia. 2022 Glaucoma Treatment Compliance Assessment Tool (GTCAT)-short

Research Support

Current Research Support

1. National Eye Institute 10/2020-10/2024 0.6 months

R01 EY020922 Blood flow and hemodynamics in glaucoma (PI: Gardiner)
The grant will examine the effect of autoregulation and blood flow perturbations on progressive glaucoma.
Total Support: \$1,843,582
Role: Co-Investigator

2. Visus 8/2022-8/2024
A 6-Month, Multicenter, Double-Masked, Randomized, Vehicle-Controlled Phase 3 Safety and Efficacy Study with a 6-Month Extension of BRIMOCHOLTM PF (Carbachol 2.75% / Brimonidine Tartrate 0.1% Fixed-Dose Combination) Topical Ophthalmic Solution vs. Carbachol PF 2.75% Monotherapy Topical Ophthalmic Solution vs. Vehicle in Subjects with Emmetropic Phakic or Pseudophakic Presbyopia
Total Support: \$300,000
Role: Principal Investigator

3. Thea 8/2022-5/2024
Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients
Total Support: \$120,000
Role: Principal Investigator

4. Perfuse 4/2023-4/2025
Efficacy and safety of the PER-001 Intravitreal Implant in glaucoma patients.
Total Support: \$236,000
Role: Principal Investigator

5. National Eye Institute 9/2023-4/2027 0.6 months
Functional Testing and Quality of Life in Glaucoma (Gardiner)
This grant will explore the relationship of glaucoma visual field loss on reading speed, balance, and patient reported outcome procedures.
Total Support: \$627,980
Role: Co-Investigator

Previous Research Support:

1. National Eye Institute 1/2021-1/2023 1.44 months
R34 EY031427 80 Years and Older Vision & Hearing Important Persons Project (80VIP)
This planning grant (R34) develops the infrastructure and recruitment strategy to determine the prevalence of undiagnosed vision loss, hearing loss, and balance disorders in pilot study of community-dwelling adults 80 years and older in Portland, Oregon.
Total Support: \$494,808
Role: Principal Investigator

2. National Eye Institute 10/2018-10/2022 0.5 months
R01 EY020922-06A1 Functional Testing in Glaucoma (PI: Gardiner)
This grant will examine new methods of detecting progressive glaucoma.
Total Support: \$2,062,500
Role: Co-Investigator

3. Allergan/Abbvie. 3/2019-10/2021

1698-302-007. An extension trial to evaluate the long-term safety and efficacy of bimatoprost SR in patients with open angle glaucoma or ocular hypertension.
Total Support: \$62,364

4. National Eye Institute 5/2018-5/2021 1.2 months
1R41EY028807 – 01. A universal eye drop adherence monitor to measure and improve adherence to ocular medications (Co-PI's Porter and Mansberger)
This grant will develop an eye dose monitor that measures adherence and connects to a wireless mobile phone for improving the measurement of eye drop adherence. Future derivations will be developed for consumer use.
Total Support: \$224,997

5. Nicox 9/2018-9/2020
A Phase 2, Randomized, Multicenter, Masked, Parallel-Group, Dose Response Study Evaluating the Safety and Efficacy of NCX 470 (3 doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension
Total Support: \$158,820
Role: Principal Investigator

6. American Glaucoma Society, ASSISTS Study 2016-2021
A Randomized controlled study to determine the efficacy of glaucoma tube insertion vs. transcleral cyclophotocoagulation for uncontrolled glaucoma
Total Support: \$300,000 to University of Texas, Houston
Role: Principal Investigator

7. National Institutes of Health, 11/2018-10/2019
Niche Assessment Program for HHS SBIR/STTR Phase I Awardees
This grant provides funds for a contractor to determine the market of new devices through the STTR program
Total Support: Direct payment from NIH to contractor
Role: Principal Investigator

8. Business Oregon 5/2019-5/2020
A universal eye drop adherence monitor
This grant will develop a detailed FDA approval strategy and a comprehensive evaluation of the manufacturing requirements and costs that will transition the research use device to a commercially available device.
Total Support: \$50,000
Role: Principal Investigator

9. National Eye Institute 5/2015-6/2019
RO1 EY025181-01 Ocular Hypertension Treatment Study (PI: Mansberger)
This study is a 20-year follow-up of patients with ocular hypertension for development of glaucoma and other eye diseases
Total Support: \$191,918
Role: Principal Investigator

10. Ocular Therapeutix 2/2017-2019
A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3a Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects with Open-Angle Glaucoma or Ocular Hypertension.

Total Support: \$122,510
Role: Principal Investigator

11. Allergan 8/2016-8/2018
A Phase-2, Multicenter, Double-Masked Randomized, Vehicle-Controlled, parallel-group study evaluating the safety, efficacy, and pharmacokinetics of the fixed combination of AGN-199201 and AGN-190584 in patients with presbyopia.
Total Support: \$183,600
Role: Principal Investigator

12. American Glaucoma Society MAPS award 1/2017-1/2/2018
Nose pivoted drop delivery device for administering glaucoma medications
Total Support: \$10,000
Role: Mentor

13. Alcon 6/2016-1/2017
24 hour intraocular pressure control with brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension vs. vehicle. (PI: Mansberger)
Total Support: \$185,807
Role: Principal Investigator

14. Allergan 3/2012-9/2015
A multicenter, Paired-eye Comparison, Dose-escalation, Single Dose, 24 month Study of Safety and Efficacy of Bimatoprost Preservative Free Intracameral Delivery System (Bimatoprost PF IC DDS) in Patients With Open Angle Glaucoma (PI: Mansberger)
Total Support: \$231,711
Role: Principal Investigator

15. National Eye Institute 8/2012-8/2016
R01 EY020922 Functional Testing for Glaucoma (PI: Gardiner)
This project will evaluate and improve functional testing for glaucoma.
Total Support: \$1,550,230
Role: Co-Investigator

16. Envisia 1/2015-1/2016
A Multi-Center, Open-Label, Parallel-Arm Randomized, Dose Ranging Study of ENV515 (travoprost) Intracameral Implant in Subjects with Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma
Total Support: \$98,765
Role: Principal Investigator

17. National Eye Institute 9/2009-8/2014
R01 EY 019674 Predicting the Rate of Progression in Glaucoma (PI: Demirel, S)
This project will determine predictive factors for progressive glaucomatous change differentiating between structure of the nerve head, or loss of retinal ganglion cell (RGC) function.
Total Support: \$1,950,000
Role: Consultant

18. Mobius Pharmaceuticals March 2013-March 2014
Breakdown products of Mitomycin C (PI: Mansberger)

This project will analyze mitomycin C (a common chemical used in glaucoma surgery) and its breakdown products using high-pressure liquid chromatography and mass spectrometry.

Total Support: \$39,600

Role: Principal Investigator

19. University of Colorado July 2011-June 2013

Motivational interviewing and glaucoma adherence (PI: Mansberger)

This project will compare motivational interviewing vs. usual care in adherence to glaucoma medications.

Total Support: \$117,737

Role: Principal Investigator

20. Centers for Disease Control and Prevention (CDC) July 2010-Feb 2013

1U48DP002673 The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy (PI: Mansberger)

This project will compare telemedicine to current surveillance mechanisms to detect diabetic retinopathy.

Total Support: \$ 2,003,926

Role: Principal Investigator

21. AHRQ. January 2011-January 2013

Glaucoma surgery outcomes (PI: Mansberger)

This project will compare trabeculectomy, trabeculoplasty, and additional medications for lowering intraocular pressure.

Total Support: \$45,200

Role: Principal Investigator

22. Allergan 5/2009-5/2010

Horizon Grant (PI: Mansberger)

This grant supports glaucoma fellowship research activities at Devers Eye Institute.

Total Support: \$50,000

Role: Principal Investigator

23. Alcon 1/2009-06/2009

Study: Protocol C-08-049 A Dose-Volume of Anecortave Acetate in Patients with Open-Angle Glaucoma or Ocular Hypertention.

To determine the effect of Anecortave Acetate on intraocular pressure

Total Support: \$99,825

Role: Principal Investigator

24. National Eye Institute 7/2000-2009

EY-10362-10 Ocular Hypertensive Treatment Study (PI: Cioffi)

The major goals of this project are to determine whether reduction of intraocular pressure with ocular hypotensive medications prevents or delays the development of glaucoma in ocular hypertensive patients.

Total Support: \$2,470,000

Role: Co-Investigator

25. National Eye Institute July 2004-2009

K23-Northwest Tribal Vision Project (PI: Mansberger)

This is a career development grant to increase Dr. Mansberger's skills in epidemiology and biostatistics.

The research project will determine whether ophthalmic technicians using new instruments of testing are

accurate in comparison to an ophthalmologist exam. It also develops preliminary information regarding the prevalence of eye diseases in Northwest American Indians and Alaskan Natives.

Total Support: \$1,170,680

Role: Principal Investigator

26. Centers for Disease Control and Prevention (CDC) October 2004-2009

Tribal Visual Impairment Prevention Program (PI: Mansberger)

The CDC selected Oregon Health Science University as a location for a Health Promotion and Disease Prevention Research Center. Dr. Mansberger is the principal investigator for the core research project to compare current surveillance methods to telemedicine with nonmydriatic cameras for detecting diabetic retinopathy in Alaskan Natives and American Indians. This study will also measure the change in quality of life with correction of refractive error.

Total Support: \$1,075,112

Role: Principal Investigator

27. Allergan July 2006-June 2008

Brimonidine Purite 0.1% TID versus Beta Blocker BID Used as Adjunctive Therapy to Latanoprost

This project determines whether brimonidine or timolol is more affective as an adjunctive treatment to latanoprost.

Total Support: \$75,141

Role: Principal Investigator

28. American Glaucoma Society. October 2005-2006.

Glaucoma Compliance Assessment Tool (PI: Mansberger)

Research into Patient Adherence to Care: The American Glaucoma Society research committee selected the Glaucoma Compliance Assessment Tool (GCAT) as their first grant for glaucoma compliance. This study develops a quantitative measure of factors affecting compliance with glaucoma treatment using the constructs of the Health Belief Model.

Total Support: \$55,000

Role: Principal Investigator

29. University of Alabama. January 2006-2007

Risk factors for noncompliance (PI: Mansberger)

This study utilizes a questionnaire to determine the factors associated with compliance with Travatan Dosing aid.

Total Support: \$92,400

Role: Principal Investigator

30. Pfizer 10/2002-2008

Risk Assessment (PI: Mansberger)

We monitor the number of eye care providers that access and download our Devers Ocular Hypertension to Glaucoma Risk Calculator.

Total Support: \$74,000

Role: Principal Investigator

31. Legacy Health System 7/2003

RAC grant

This grant supported a nonmydriatic camera for our telemedicine protocol

Total Support: \$19,800

Role: Principal Investigator

32. Legacy Health System 7/2003

RAC grant

This grant supported staffing costs for analyzing data from a glaucoma screening in Southern India.

Total Support: \$17,591

Role: Principal Investigator

33. Santen 9/2001-12/2001

AFB-168 (PI: Mansberger)

The study will investigate the dose-response relationship of AFP-168 with concentrations of 0.001%, 0.0025%, and 0.005%. It will also compare the safety and efficacy of these three concentrations with placebo and 0.005% latanoprost.

Total Support: \$82,344

Role: Principal Investigator

34. National Eye Institute / SBIR 3/01/02 to 9/01/02

Aqueous Vein Drain Tube (PI Swanson)

The Major Goals of this project are to examine the magnitude of protein and cell binding with various bioactive coatings and polymers.

Total Support: \$43,099

Role: Co-Investigator

35. Allergan 8/2003-8/2004

019T (PI: Mansberger)

This study compares the hypotensive efficacy of 019T (combination of Timolol and Brimonidine) with individual administration of Timolol and Brimonidine.

Total Support: \$84,000

Role: Principal Investigator

36. Collins Foundation 07/1999-08/2003

Screening with Frequency Doubling Technology (FDT) in the Community

This study compares the screening accuracy of FDT for detecting eye diseases and glaucoma in the community.

Total Support: \$800,000

Role: Co-Investigator

37. Allergan 12/2000-6/2007

Memantine (PI: Mansberger)

This randomized control trial examines whether Memantine (an NMDA receptor antagonist) prevents progressive functional and structural changes from glaucoma.

Total Support: \$890,000

Role: Principal Investigator

38. Allergan 1/2006-2008

A multicenter, double-masked, randomized, parallel, active-controlled /three month study (plus 9-month masked extension) of the safety and efficacy of bimatoprost ophthalmic solution 0.01% and Bimatoprost Ophthalmic solution 0.0125% once-daily compared with Lumigan (Bimatoprost ophthalmic solution 0.03% once-daily in patients with glaucoma or ocular hypertension. (PI: Cioffi)

Total Support: \$79,000

Role: Co-Investigator

39. American Glaucoma Society. October 2004-2005.

Tribal Vision Project (PI: Mansberger)

This study was a continuation of a funded grant to determine the prevalence of eye diseases in American Indian/Alaskan Natives.

Total Support: \$45,000

Role: Principal Investigator

40. American Glaucoma Society. October 2003-2004.

Tribal Vision Project (PI: Mansberger)

This study was the original grant to determine the prevalence of eye diseases in American Indian/Alaskan Natives.

Total Support: \$45,000

Role: Principal Investigator

41. Alcon Sept 2003-2004

Tribal Vision Project (PI: Mansberger)

This study was a continuation of a funded grant to determine the prevalence of eye diseases in American Indian/Alaskan Natives.

Total Support: \$29,000

Role: Principal Investigator

Invited CME Presentations/lectures (Domestic and International):

1. Grand Rounds, Oregon Health Science University. April 2000. "Screening for glaucoma"
2. Kaiser Regional Conference, Santa Monica, CA. July 2001. Functional Testing of glaucoma for the clinician" and "Ocular Hypertension"
3. Vision 2000, Portland, OR. September 2001. "Screening for glaucoma using Frequency Doubling Technology perimetry"
4. Subspecialty Day, American Academy of Ophthalmology. October 2001. "Blebitis: recognition and treatment"
5. Grand Rounds, Oregon Health Science University. April 2002. "How to practice evidenced-based ophthalmology"
6. Thorny Issues, Portland, OR. June 2002. "Trabeculectomy Postoperative Management" and "Evidenced Based Ophthalmology"
7. Ophthalmology Update, Skamania Lodge, Portland, OR. June 2003. "Cataract surgery before Trabeculectomy", "Examining the optic disc", and "Difficult Glaucoma: Case Presentations"
8. OHSU Alumni Meeting, Portland, OR. September 2003. "Postoperative trabeculectomy management"
9. Bridgeport Glaucoma Society, Portland, OR. October 2003. "Predicting Glaucoma from Ocular Hypertension: The Glaucoma Risk Calculator"
10. Yale Annual Glaucoma Symposium. October 2003. "Treating the patient not the intraocular pressure", "Making the decision to operate", and "Selective Functional testing for the clinician"
11. Alcon Fellows Program, Ft. Worth, TX. November 2003. "Are Glaucoma and Ischemia related? An evidenced-based approach"
12. Subspecialty Day, American Academy of Ophthalmology. November 2003. "Episcleral Venous Pressure and Glaucoma".
13. Ophthalmology Grand Rounds. May 2004. "Treating Ocular hypertension based on Risk: The Devers Ocular Hypertension to Glaucoma Risk calculator"
14. Thorny Issues, Portland, OR. June 2004. "Glaucoma: A public health crisis?"
15. Medical Grand Rounds, Legacy Health System, Portland, OR. September 2004. "Treating Ocular hypertension based on Risk: The Devers Ocular Hypertension to Glaucoma Risk calculator"
16. Pan American Academy of Ophthalmology. Santiago, Chili. March 2005. "Selective Functional Testing of Glaucoma"

17. Pan American Academy of Ophthalmology. Santiago, Chili. March 2005. "Treatment of overfiltration following glaucoma surgery"
18. Thorny Issues, Portland, OR. June 2005. "Case Presentations in Glaucoma"
19. Optometry Grand Rounds, Veterans Administration Hospital VISN area Northwest. Portland, OR. July 2005. "Large Clinical Trials in Glaucoma".
20. Internal Medicine Grand Rounds, Providence Health System. Portland, OR. July 2005.
21. Subspecialty Day, American Academy of Ophthalmology. November 2005. "Recognizing Pre-perimetric glaucoma".
22. Vancouver Clinical Day, Vancouver, Canada. January 2006. "Evaluation of the optic disc: HRT, GdX, OCT, and the 78 dpt lens", "Risk Calculators for Ocular Hypertension", "Recognizing Glaucomatous Progression", "Prevention Postoperative IOP spikes", "My trabeculectomy technique", "One-eyed trials under fire".
23. Ophthalmology Grand Rounds, Oregon Health Science University. Portland, Oregon. January 2006. "Good Blebs gone Bad"
24. World Ophthalmology Congress, Sao Paulo, Brazil. February 2006. "Postoperative Antimetabolites; How I do it".
25. Grand Rounds, University of West Virginia, Morgantown, WV. May 2006. "Glaucoma –Risk, Evaluation, Assessment, and Treatment".
26. Thorny Issues, Devers Eye Institute, Portland, OR. June 2006. "Lessons from the Ocular Hypertension Treatment Study."
27. Improving Your Odds, Ocular Surgery News. Las Vegas, NV. June 2006. "Risk Factors for Glaucoma."
28. Optometry Grand Rounds, Veterans Administration Hospital VISN area Northwest. Portland, OR. September 2006. "Lessons from the OHTS study".
29. Academy for Healthcare Education, Newark, NJ. September 2006. "Great Expectations: Glaucoma Risk Evaluation and Treatment."
30. Academy for Healthcare Education, Honolulu, HI. October 2006. "Great Expectations: Glaucoma Risk Evaluation and Treatment."
31. Grand Rounds, Wills Eye Hospital, Philadelphia, PA. October 2006. "Glaucoma –Risk, Evaluation, Assessment, and Treatment".
32. American Academy of Ophthalmology, Subspecialty Day. November 2006. "Can you predict which patients are noncompliant?"
33. Improving Your Odds, American Academy of Ophthalmology. Las Vegas, NV. November 2006. "Risk assessment in glaucoma: lessons from OHTS and EGPS"
34. Academy for Healthcare Education, Seattle, WA. December 2006. "Great Expectations: Glaucoma Risk Evaluation and Treatment."
35. Ski Vision, Snowmass, CO. February 2007. "Determining the risk of blindness from glaucoma"; "Objective structural testing for glaucoma"; and "Cases in glaucoma".
36. International Glaucoma Symposium, Singapore. July 2007. "Risk calculators in Glaucoma", "Target Intraocular Pressure", "Risk and Health Economic models"
37. Thorny Issues, Portland, OR. September 2007. Neurophthalmology Panel Moderator.
38. Devers/Casey Grand Rounds, Portland, OR. September 2007. "Treating compliance"
39. North American Perimetry Society. September 2007. Skanataelas, NY. "Screening for Breast Cancer, Prostate Cancer. Why not Glaucoma"
40. VISN Optometry Grand Rounds. November 2007. Portland, Oregon. Improving compliance in glaucoma patients".
41. University of Colorado (February 2008). Denver, Colorado. Visiting Professor Grand Rounds. "Treating your patients, not just the intraocular pressure".
42. American Glaucoma Society (March 2008). Washington, DC. "Predictive Factors for following up with an Eye Care Provider"

43. University of Missouri, Kansas City Grand (April 2008). Kansas City, MS. Visiting Professor Grand Rounds. "Treating noncompliance using the Health Belief Model"
44. Arizona Ophthalmology Society Annual Meeting (May 2008). Sedona, AZ. "Good Blebs Gone Bad" and "Losing the battle of glaucoma: Signs of glaucomatous progression"
45. American Academy of Ophthalmology, Subspecialty Day. Atlanta, GA. November 2008. "Screening for glaucoma using perimetry?"
46. American Academy of Ophthalmology. Atlanta, GA. November 2008. "Good blebs gone bad"
47. VISN Optometry Grand Rounds. December 2008. Portland, Oregon. "Lessons from the Ocular Hypertension Treatment Study." Improving compliance in glaucoma patients".
48. Distinguished Alumni Lecture. June 2009. Shiley Eye Center, University of California, San Diego. San Diego, CA. "Treating the patient, not just the intraocular pressure"
49. American Academy of Ophthalmology. October 2009. San Francisco, CA. "When to needle after glaucoma surgery".
50. VISN Optometry Grand Rounds. January 2010. Portland, Oregon. "Case Studies in Glaucoma."
51. Western Regional Meetings of the American Federation of Medical Research. January 2010. Carmel, CA. "Telemedicine to detect Diabetic Retinopathy in American Indian/Alaska Natives and Other Ethnicities"
52. Bascom Palmer Midwinter Forum-Battle on the Beach. January 2010. Miami, FL. "Detection of glaucomatous optic disc progression" and "Treating the postoperative bleb".
53. American Telemedicine Association. April 2010. San Antonio, Tx. "Progression of diabetic retinopathy in American Indian/Alaskan Natives using a telemedicine system"
54. SOPHE-PRC 2010 Joint Conference. April 2010. Atlanta, GA. "Using telemedicine to detect diabetic retinopathy"
55. World Ophthalmology Congress. June 2010. Berlin, Germany. "Clinical use of risk calculators for managing glaucoma"
56. Thorny Issues. September 2010. Portland, OR. "Clinical cases in Glaucoma".
57. American Academy of Ophthalmology, Subspecialty Day. Chicago, IL. October 2010. "Barriers to Glaucoma Adherence"
58. American Academy of Ophthalmology, Media Day. Chicago, IL. October 2010. "Common eye problems in American Indians/Alaskan Natives".
59. American Academy of Ophthalmology, Chicago, IL. October 2010. "Needling revision of trabeculectomy blebs".
60. American Academy of Ophthalmology, Editors' Choice Awards. Chicago, IL. October 2010. "Comment: Rates of progressive retinal NFL loss in Glaucoma Measured by Scanning Laser Polarimetry".
61. American Academy of Ophthalmology, Chicago, IL. October 2010. "Trabeculectomy Laboratory Course"
62. Telemedicine Association of Oregon. November 2010. Portland, OR. "Legacy Telehealth and TeleOphthalmology"
63. Berglund Invited Lecturer. Berglund Center for Internet Studies, Pacific University. November 2010. Portland, OR. "Northwest Tribal Vision Project: Diabetic Eye Disease Detection Non-mydratic Retinal Cameras"
64. American Glaucoma Society. March 2011. Irving, CA. "Effect of Cataract Surgery on IOP in the OHTS Observation Group"
65. OHSU/Legacy Health System Ophthalmology Grand Rounds. April 2011. Portland, OR. "Ophthalmology Lessons from Studies in American Indian/Alaskan Natives"
66. World Glaucoma Association. July 2011. Paris, France. "Sleep Apnea and Glaucoma, Are they related?"
67. World Glaucoma Association. Best of the American Glaucoma Society. July 2011. Paris, France. "Effect of Cataract Surgery on IOP in the OHTS Observation Group"
68. Thorny Issues. Sept 2011. Portland, OR. "Cases in glaucoma: the good, bad, and ugly"

69. Sally Letson Conference. Sept 2011. Ottawa, Canada. "Cataract surgery: the 'new' treatment for glaucoma"
70. Sally Letson Conference. Sept 2011. Ottawa, Canada. "Screening for breast, cervical, and prostate cancer: Why not glaucoma".
71. Sally Letson Conference. Sept 2011. Ottawa, Canada. "Continuous IOP monitoring: ready for primetime?"
72. American Academy of Ophthalmology. October 2011. Orlando, FL. Glaucoma Subspecialty Day Moderator: "Update on Structure and Function".
73. American Academy of Ophthalmology. October 2011. Orlando, FL. Best of Anterior Segment meetings: "Reduction in intraocular pressure after cataract extraction in The Ocular Hypertension Treatment Study (OHTS)."
74. American Academy of Ophthalmology. October 2011. Orlando, FL. Paper session. "Change in intraocular pressure after cataract extraction in The Ocular Hypertension Treatment Study (OHTS)."
75. American Academy of Ophthalmology. October 2011. Orlando, FL. Instruction course. "Managing the failing bleb".
76. American Public Health Association annual meeting. October 2011. Washington, DC. "The comparative effectiveness of telemedicine to detect diabetic retinopathy".
77. American Glaucoma Society. March 2012. "AGS Video Awards". Moderator.
78. Oregon Academy of Ophthalmology. March 2012. Moderator
79. Ophthalmology Resident Day. March 2012. Calgary, Canada. "Imaging in Glaucoma" and "Risk factors in Glaucoma".
80. Ophthalmology Grand Rounds. March 2012. Calgary, Canada. "Knowing you are losing the battle with glaucoma"
81. Israel Glaucoma Today. March 2012. Tel Aviv, Israel. "Treating the failing bleb", "Progression in glaucoma", "Lessons from large randomized controlled trials"; "Continuous IOP monitoring-are we there yet?"; "Glaucoma cases"; "Ocular surface disease and glaucoma medications".
82. Cook, P. F., Mansberger, S. L., Sheppler, C., Schmiege, S. J., & Kahook, M. Y. (2012, April). Glaucoma medication treatment nonadherence: Correlates and consequences. Podium presentation at the Western Institute of Nursing (WIN) conference, Portland OR
83. Ophthalmology Grand Rounds. September 2012. Portland, OR. "Cataract surgery, the new glaucoma surgery?"
84. Nebraska Academy of Ophthalmology. October 2012. Omaha, NE. "Cataract surgery, the new glaucoma surgery?", "Knowing you are losing the battle with glaucoma",
85. American Public Health Association Annual Meeting. October 2012. San Francisco, CA. "The long-term Comparative Effectiveness of Telemedicine for detecting Diabetic retinopathy".
86. American Academy of Ophthalmology Annual Meeting. October 2012. Chicago, IL. "Be compliant in recognizing poor adherence in your patient".
87. American Academy of Ophthalmology Annual Meeting. October 2012. Chicago, IL. "Trabeculectomy: Tips and traps lecture course".
88. Ophthalmology Grand Rounds, Visiting Professor. November 2012. Baylor University. Houston, Tx. "It's Risky not using Risk assessment when evaluating your glaucoma patients".
89. Houston Ophthalmology Society Lecture. November 2012. Houston, Tx. "Cataract surgery, the new glaucoma surgery?".
90. Ophthalmology Grand Rounds, Visiting Professor. November 2012. University of Texas, Houston. "Knowing you are losing the battle with glaucoma".
91. American Glaucoma Society, March 2013. San Francisco, CA. Moderator: "AGS Video Awards"
92. American Glaucoma Society, March 2013. San Francisco, CA. Lecturer "Staffing in the era of EMR" Electronic Record Symposium"
93. American Society of Cataract and Refractive Surgery (ASCRS), Glaucoma Day, April 2013. San Francisco, CA. "The case for cataract surgery as a glaucoma procedure".

94. Optometry Grand Rounds, Veterans Hospital. May 2013. Portland, OR. "Cataract surgery: A new treatment for glaucoma?'
95. Central Oregon Glaucoma Symposium. May 2013. Brasada Ranch, OR. "Ocular Hypotensive medications: what you forgot to ask", "Good, Bad, and Ugly glaucoma Cases", "It's Risky to not assess Risk in glaucoma".
96. Thorny Issues, Sept 2013. Portland, OR. Moderator: "Glaucoma Cases"
97. American Academy of Ophthalmology. November 2013. The Great Debate in Glaucoma. "For Cataract and Glaucoma Controlled on Medication, I prefer Cataract Surgery".
98. American Academy of Ophthalmology. Didactic course. November 2013. "Trabeculectomy: How to maximize your success".
99. 53rd Annual Walter Wright Day: Glaucoma Management^(SEP) Review Course, December 2013. Toronto, Canada. "What to do with patients with high IOP and normal visual fields"
100. 53rd Annual Walter Wright Day: Glaucoma Management^(SEP) Review Course, December 2013. "Phaco: the latest treatment for glaucoma?"
101. 53rd Annual Walter Wright Day: Glaucoma Management^(SEP) Review Course, December 2013. Moderator. "Glaucoma Under Medication".
102. 53rd Annual Walter Wright Day: Glaucoma Management^(SEP) Review Course, December 2013. Moderator. "Glaucoma Under Attack".
103. Cook, P. F., Schmiede, S. J., Mansberger, S. L., Kammer, J., & Kahook, M. (2014, March). Motivational interviewing for glaucoma medication adherence: Results of a multi-site RCT. Podium presentation at the Western Institute of Nursing (WIN) conference, Seattle WA
104. University of Kansas City Medical Center, Kansas City, KS. Annual Update in Ophthalmology. June 2014. "Recognizing that you are losing the battle of glaucoma".
105. University of Kansas City Medical Center, Kansas City, KS. Annual Update in Ophthalmology. June 2014. "Continuous IOP monitoring for glaucoma".
106. Thorny Issues, Sept 2014. Portland, OR. Moderator: "Glaucoma Cases"
107. Eye Vitals, October 2014. Portland, OR. "Watch Out! Ocular Side Effects of Common Systemic Medications"
108. VA Optometry Grand Rounds, October 2014. "Continuous IOP monitoring, Ready for prime time?"
109. American Academy of Ophthalmology, Chicago, IL. October 2014. Moderator, Prevent Blindness Symposium, "The Great Debate in Glaucoma".
110. American Academy of Ophthalmology, Chicago, IL. October 2014. Course Director and Lecturer, "Trabeculectomy: Tips and traps".
111. American Academy of Ophthalmology, Chicago, IL. October 2014. Course Director and Instructor, "Trabeculectomy Wet Lab".
112. American Academy of Ophthalmology, Chicago, IL. October 2014. Discussant of Glaucoma Original Papers.
113. Oregon Chapter of the American College of Physicians, Salem, OR. November 2014. "Seeing Red: Approach to the Red Eye"
114. Optometric Glaucoma Society, Denver, CO. November 2014. "Continuous IOP Monitoring: Ready for Primetime?"
115. Optometric Glaucoma Society President's Lecture, Denver, CO. November 2014. "Glaucomatous Adherence, the Iceberg below the Surface"
116. American Academy of Optometry, Denver, CO. November 2014. "Cataract surgery: the new glaucoma surgery?"
117. Cole Eye Institute at Cleveland Clinic Visiting Scholar lecture. November 2014. "Cataract surgery: the new glaucoma surgery"
118. American Glaucoma Society Annual Meeting, March 2015. Moderator. Paper session.
119. Association for Eye Vision Research (AEVR) Glaucoma Awareness Week Lecturer at the US Congress, March 2015. Washington, DC

120. World Glaucoma Association. "Glaucoma Surgery - New Surgical Techniques & Unmet Needs". June 2015. Hong Kong, China
121. World Glaucoma Association. "Basic Trabeculectomy Set Up, Managing the Postop Bleb w Massage". June 2015. Hong Kong, China.
122. World Glaucoma Association. "How I know the visual field is reliable". June 2015. Hong Kong, China.
123. Thorny Issues. "Complex Cases in Glaucoma" September 2015. Portland, OR.
124. American Academy of Ophthalmology, Las Vegas, NV. October 2015. Course Director and Lecturer, "Trabeculectomy: Tips and traps".
125. American Academy of Ophthalmology, Las Vegas, NV. October 2015. Course Director and Instructor, "Trabeculectomy Wet Lab".
126. American Academy of Ophthalmology, Las Vegas, NV. October 2015. Glaucoma Subspecialty Day "Patient with early glaucoma is getting worse, What now?"
127. American Academy of Ophthalmology, Las Vegas, NV. October 2015. Moderator, Prevent Blindness Symposium, "The Great Debate in Glaucoma".
128. American Academy of Ophthalmology, Las Vegas, NV. October 2015. "Preferred Practice Patterns for Primary Open Angle Glaucoma: Definitions, Prevalence and Risk Factors."
129. University of British Columbia Grand Rounds. January 2016. "Cataract: the new glaucoma surgery?"
130. University of British Columbia. Visiting Professor. January 2016. "Cases in glaucoma".
131. American Glaucoma Society Annual Meeting. March 2016. Moderator. "The Great Debate in Glaucoma Epidemiology"
132. Canadian Glaucoma Society Annual Meeting. April 2016. "Knowing you are losing the battle of glaucoma"
133. Canadian Glaucoma Society Annual Meeting. April 2016. "New surgical treatments for glaucoma with unmet needs".
134. Alabama Alumni Sponsored Lecturer. "Cataract: the new glaucoma surgery?". Birmingham, AL. May 2016
135. Alabama Alumni Sponsored Lecturer. "Knowing you are losing the battle of glaucoma". Birmingham, AL. May 2016
136. Errors In Retinal Nerve Fiber Layer Thickness Measurements Using Automated Segmentation Of Optical Coherence Tomography. AOS. Colorado Springs, CO. June 2016
137. Sustained glaucoma delivery devices. European Glaucoma Society. Prague, Czech Republic. June 2016.
138. Thorny Issues. "The great debate of glaucoma in an election year". Portland, OR. September 2016.
139. American Academy of Ophthalmology, Chicago, IL. October 2016. Course Director and Lecturer, "Trabeculectomy: Tips and traps".
140. American Academy of Ophthalmology, Chicago, IL. October 2016. Course Director and Instructor, "Trabeculectomy Wet Lab".
141. Oral Board Examiner, American Board of Ophthalmology. San Francisco, CA. October 2016.
142. University of Sao Paulo 100th anniversary meeting. Sao Paulo, Brazil. December 2016. Honorary Speaker. "Continuous IOP monitoring, ready for primetime?"
143. University of Sao Paulo 100th anniversary meeting. Sao Paulo, Brazil. December 2016. Honorary Speaker. "How to be compliant in addressing glaucoma adherence"
144. University of Sao Paulo 100th anniversary meeting. Sao Paulo, Brazil. December 2016. Honorary Speaker. "Cataract vs. Cataract + surgery: How should I treat my glaucoma patient?"
145. Columbia University. New York City, NY. January 2017. Special invited lecturer. "How to be compliant in addressing glaucoma adherence"
146. Columbia University. New York City, NY. January 2017. Basic Clinical Science Series lecturer. "Preventing and treating glaucoma surgical complications"
147. Research Study Group, Los Angeles, CA. January 2017. "How to be compliant with glaucoma adherence"

148. Research Study Group, Los Angeles, CA. January 2017. "Knowing you are losing the battle of glaucoma"
149. Research Study Group, Los Angeles, CA. January 2017. "Cataract vs. Cataract/MiGS-How do I decide?"
150. VA Optometry Grand Rounds, Portland, OR. February 2017. "Knowing you are losing the battle of glaucoma"
151. American Glaucoma Society, Coronado, CA. March 2017. "When to choose MIGS in addition to cataract surgery"
152. American Glaucoma Society, Coronado, CA. March 2017. "Low Dose ENV515 Travoprost Safety and Efficacy at 9 months."
153. American Society of Cataract and Refractive Surgery (ASCRS). Los Angeles, CA. May 2017. ""When to choose MIGS in addition to cataract surgery"
154. World Glaucoma Congress, Helsinki, Finland. June 2017. "Target IOP and when to initiate ocular hypotensive medications".
155. World Glaucoma Congress, Helsinki, Finland. June 2017. "Risk profiling for angle closure glaucoma"
156. Atlantic Eye Symposium, Halifax, Nova Scotia. Sept 2017. "Knowing you are losing the battle of glaucoma"
157. Atlantic Eye Symposium, Halifax, Nova Scotia. Sept 2017. "Cataract vs. Cataract + surgery: How should I treat my glaucoma patient?"
158. Thorny Issues in Ophthalmology. Oct 2017. Glaucoma Cases discussion
159. American Academy of Ophthalmology, New Orleans. November 2017. Course Director and Lecturer, "Trabeculectomy: Tips and traps".
160. American Academy of Ophthalmology, New Orleans. November 2017. Course Director and Instructor, "Trabeculectomy Wet Lab".
161. American Academy of Ophthalmology, New Orleans. November 2017. Moderator. Glaucoma Free Paper Session.
162. Legacy Ophthalmology Grand Rounds, Portland, Oregon. December 2017. "Cataract vs. Cataract + surgery: How do I decide?"
163. Canadian Glaucoma Society annual meeting, Whistler, Canada. January 2017. "Platforms and Pitfalls for OCT imaging of the optic disc".
164. Canadian Glaucoma Society annual meeting, Whistler, Canada. January 2017. Panel member. "Incorporating minimally invasive glaucoma surgeries into your surgical armamentarium."
165. American Ophthalmology Society (American Ophthalmological Society). Dana Point, California. May 2018. " Peripapillary retinoschisis (PPRS) in glaucoma".
166. Medical College of Wisconsin, Milwaukee, Wisconsin. June 2018. "Knowing you are losing the Battle of glaucoma"
167. Thorny Issues in Ophthalmology. Legacy Health System, Portland, OR. October 2018. "Cases in Glaucoma".
168. American Academy of Ophthalmology, Chicago, IL. October 2018. Course Director and Lecturer, "Trabeculectomy: Tips and traps".
169. American Academy of Ophthalmology, Chicago, IL. October 2018. Instructor, "Trabeculectomy Wet Lab".
170. Visiting Professor of Ophthalmology. Philadelphia, PA. December 2018. "Cases in Glaucoma with the socratic method".
171. Visiting Professor of Ophthalmology. Philadelphia, PA. December 2018. "Cataract vs. Cataract +".
172. Visiting Professor of Ophthalmology. Philadelphia, PA. December 2018. "How you know you are losing the battle of glaucoma".
173. Glaucoma 360 meeting. San Francisco, CA. January 2018. Symposium leader of Bausch & Lomb, Aerie, and Santen.

174. VA Optometry Grand Rounds, May 2019. Portland, OR. "Find the glaucoma diagnosis using the interactive Socratic method".
175. Thorny Issues, September 2019. Portland, OR. "Knowing you are losing the battle of glaucoma".
176. Thorny Issues, September 2019. Portland, OR. "Cases in glaucoma"
177. American Academy of Ophthalmology, San Francisco, CA. October 2019. Course Director and Lecturer, "Trabeculectomy: Tips and traps".
178. American Academy of Ophthalmology, San Francisco, CA. October 2019. Instructor, "Trabeculectomy Wet Lab".
179. Devers/OHSU grand rounds. Portland, OR. February 2020. "Complex glaucoma cases spanning retina, pediatrics, cornea, and more".
180. American Glaucoma Society National Meeting. Free Paper session, moderator. Washington DC, February 2020.
181. Oregon Health Science University and Portland State University Department of Epidemiology, "Lessons in epidemiology from ophthalmology studies in American Indians". April 2020
182. Oregon Health Science University Geriatrics fellowship program. "Eye disease in the Elderly". April 2020.
183. Oregon Health Science University Ophthalmology residency program. "Glaucoma Surgery Day". July 2020.
184. Oregon Health Science University Ophthalmology residency program. "Trabeculectomy". October 2020.
185. American Academy of Ophthalmology, (Virtual-Las Vegas). November 2020. Course Director and Lecturer, "Trabeculectomy: Tips and traps".
186. American Academy of Ophthalmology, (Virtual-Las Vegas). November 2020. "Primary Angle-Closure Disease Preferred Practice Pattern"
187. American Academy of Ophthalmology, (New Orleans). November 2021. "Innovations in visual field testing"
188. American Academy of Ophthalmology, (New Orleans). November 2021. "NCX 470 for IOP Lowering: Results of Responder Analyses From the Phase 2 Dolomites Trial"
189. American Academy of Ophthalmology, (New Orleans). November 2021. "The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)"
190. American Academy of Ophthalmology, (New Orleans). November 2021. "Trabeculectomy Techniques"
191. American Glaucoma Society (Nashville). March 2022.
192. Association for Research in Vision and Ophthalmology (ARVO). Denver, CO. May 2022. "Patient Reported Outcome Measures while using a device to objectively measure eye drop adherence."
193. Brazilian Ophthalmology Society (Sao Paulo, Brazil (virtual)). July 2022. "Updates from the Ocular Hypertension Treatment Study"
194. Thorny Issues in Ophthalmology. (Portland, Oregon). Sept 2022. "Cataract Surgery vs. Cataract +".
195. American Academy of Ophthalmology, (Chicago). Sept 2022. "Trabeculectomy Techniques"
196. American Academy of Ophthalmology, (Chicago). Sept 2022. "Trabeculectomy Lab course"
197. American Glaucoma Society, (Austin, TX), Feb 2023. "Moderator research paper section".
198. World Glaucoma Congress, (Rome, Italy), June 2023. "How to (re)organize Glaucoma Treatment Strategies"
199. World Glaucoma Congress, (Rome, Italy), June 2023. "Debate. Diabetes a risk factor for glaucoma".
200. American Academy of Ophthalmology. (San Francisco, CA). November 2023. Detecting progressive glaucoma at the AAO Learning Lounge.
201. American Academy of Ophthalmology (San Francisco, CA). November 2023. Co-Chair of Subspecialty Day and Moderator of Structure and Function section.
202. American Glaucoma Society (Huntington Beach, CA), March 2024. "Epidemiology paper session moderator"

203. American Glaucoma Society (Huntington Beach, CA). March 2024. Young Ophthalmology Glaucoma Specialists panelist. "How to increase office efficiency"
204. All Indian Ophthalmology Society Meeting (Kolkata, India). March 2024. "How to use OCT in the clinic."
205. All Indian Ophthalmology Society Meeting (Kolkata, India). March 2024. "Which MIGS to choose?"
206. All Indian Ophthalmology Society Meeting (Kolkata, India). March 2024. "How you know you are losing the battle of glaucoma".
207. All Indian Ophthalmology Society Meeting (Kolkata, India). March 2024. "How to get your paper published, Advanced and Basic Statistics".

OHSU/Devers Ophthalmology Residents

1. Oswald Binford, MD
2. Terry Wood, MD
3. Paul Finley, MD
4. Silvio Gurdian, MD
5. Jennifer Balentine, MD
6. Thuy Nguyen, MD
7. Dustin Herringer, MD
8. Christopher Barone, MD
9. Sandy Chen, MD
10. Christine Richards,
11. Jonathon Solomon, MD
12. Depali Rajguru, MD
13. Eric Steele, MD
14. Andrew Westfall, MD
15. Jane Gilbert, MD
16. Thomas Myers, MD
17. Rebecca Armour, MD
18. Kristi Bailey, MD
19. Matthew Giegengack, MD
20. Laurel Quinn, DO
21. Oday Alsheikh, MD
22. Rebecca Dale, MD
23. Hall McGee, MD
24. Tiffany Wong, MD
25. Michael Lloyd, MD
26. Kevin Michaels, MD
27. Ricardo Santaella, MD
28. Erik Letko, MD
29. David Dance, MD
30. Lorrina Lombardi, MD
31. Amanda Richards, MD
32. Shad Saunders, MD
33. Dilsher Dhoot, MD
34. Dinelli Monson, MD
35. Michael Page, MD
36. Angela Watkins, MD
37. Rebekah Allen, MD
38. Ellen Davis, MD
39. Lani Hoag, MD
40. Naveen Rao, MD

41. Justin Wilkinson, MD
42. Alan Bengtzen, MD
43. Jack Courtney, MD
44. Jennifer Rose-Nussbaumer
45. Shandiz Tehrani, MD
46. Daniel Tu, MD
47. Blake Acohido, MD
48. Rory Allar, MD
49. Ambar Faridi, MD
50. Laura Gadzala, MD
51. Kamden Kopani, MD
52. Stephanie Kramer, MD
53. Matthew Raeker, MD
54. Seema Gupta, MD
55. Jacqueline Ng, MD
56. Manjool Shah, MD
57. Grant Aaker, MD
58. Jardine Griffin, MD
59. Anthony Grillo, MD
60. Laura Kopplin, MD
61. Benjamin Siatu'u, MD
62. Daniel Lattin, MD
63. Nisha Nagarkatti-Gude, MD
64. Rasna Sandhu, MD, MPH
65. David Simons, MD, PhD
66. Akshay Thomas, MD
67. Erin Boese, MD
68. Hillary Stiefel, MD
69. Dong-Wouk Park, MD
70. Bryce Radmall, MD
71. Fran Wu, MD
72. Brock Alonzo, MD
73. Brigid Marshall, MD
74. Meryl Sundy, MD
75. Jonathan Young, MD, PhD
76. Tim Boyce, MD
77. Matt Duggan, MD
78. Kishan Gupta, MD, PhD
79. Brad Henricksen, MD
80. Travis Redd, MD, MPH
81. Caitlin Kakigi, MD
82. Nathan Lambert, MD
83. Nathan Law, MD
84. Joseph Simonett, MD
85. Kellyn Smith, MD
86. Ian Danford, MD
87. Sarah Glass, MD
88. Miles Greewald, MD
89. Michal Gutowski, MD
90. Joel Kulzny, MD
91. Marcus Altman, MD

92. Michael Gale, MD
93. Ross Passo, MD
94. Alexander Walters, MD
95. Claudine Yee, MD
96. Adam Hanif, MD
97. Ashlin Joye, DO
98. Kaitlin Kogachi, MD
99. Daniel Lee, MD
100. Claire Mueller, MD

Glaucoma Fellows

1. Kai Goh, MD. 2003. Location: Perth, Australia
2. Christopher Engleman, MD. 2003. Location: Stanford University, Stanford, CA
3. Kevin Pikey, MD. 2003. Location: University of Kansas, Kansas City, KS
4. Annisa Jamil, MD. 2004. Location: Seattle, WA
5. Emily Patterson, MD. 2004. Location: Portland, OR
6. Rodrigo Torres, MD. 2005. Location: Palm Springs, CA
7. Hau Nguyen, MD. 2005. Location: San Jose, CA
8. Hung Pham, MD. 2007. Location: Orange County, CA
9. Paul McKenzie, MD, PhD. 2008. Location: Vancouver, BC. Canada
10. Zachary Hoffelt, MD. 2009. Location: Portland, OR.
11. Michael Lloyd, MD. 2009. Location, Provo, UT
12. Indira Paudahal, MD. 2009. Kathmandu, Nepal.
13. Marta Pazos, MD. 2009. Barcelona, Spain
14. Christopher Shen, MD. 2010. Alexandria, VA
15. Yvonne Chu, MD. 2011. Baylor University, Houston, Tx.
16. Asem Alqudah, MD. 2011. King Abdullah Hospital, Irbid, Jordan
17. Robert Kinast, MD. 2011. Portland, OR
18. Hana Takasugawa, MD. 2012. Portland, OR
19. Derek Pau, MD. 2012. Atlanta, GA
20. Helen Koenigsman, MD. 2013. Medford, OR
21. Igor Estrovich, MD. 2014. Cleveland, OH
22. Pui Yi Boey, MD. 2014. Singapore National Eye Institute
23. Shivali Menda, MD. 2015. University of Washington, Seattle, WA.
24. Eliesa Ing, MD. 2015. Veterans Administration Hospital, Portland, OR.
25. Kelly Ma, MD. 2016. Kaiser, Portland, OR
26. Brendan Butler, MD. 2016. Medford, OR
27. David Simons, MD, PhD. 2017. Vancouver, WA
28. Nisha Nigakatti-Gude, MD, PhD. 2017. Portland, OR
29. Yung-Tai Kung, MD. 2018. Sonoma, CA.
30. Jessica Moon, MD. 2018. Boston, MA.
31. David Sanders, MD, MPH. 2019 Portland, OR
32. Eugene Lowry, MD. 2019 San Francisco, CA
33. Elizabeth Cretara, MD. 2020 Salt Lake City, UT.
34. Seth Bricel, MD. 2020 Port Townsend, WA
35. Karine Duarte-Bjorkian, MD. 2021 Seattle, WA
36. Bennett Hong, MD. 2021 New York, New York
37. Kaileen Yeh, MD. 2022 San Francisco, CA
38. Nicholas Grissom, MD. 2022 Fayetteville, NC
39. Alex Robin, MD. 2023 Current Fellow

Book Review

1. Campbell DG and Netland PA. Stereo Atlas of Glaucoma. 1st Ed. CV Mosby, 1998. J Glaucoma.
2. Tasman W and Jaeger EA. The Wills Eye Hospital Atlas of Clinical Ophthalmology. Lippincott-Raven. 1996. J Glaucoma

Published Abstracts

1. **Mansberger SL**, Harris A, Arend O, etal. Small PCO₂ Changes Significantly Alter Retinal Flow Indices as Measured by the Scanning Laser Ophthalmoscope. Invest Ophthalmol Vis Sci. 1993; 34 (Suppl): 1395
2. **Mansberger SL**, Harris A. Acute Effect of Apraclonidine on Perimacular Hemodynamics. Invest Ophthalmol Vis Sci. 1994; 35 (Suppl): 2176.
3. **Mansberger SL**, Sample PA, Weinreb RN. Short Wavelength Perimetry in Patients with Large Cups and Normal Automated Achromatic Visual Fields. Invest Ophthalmol Vis Sci. 1998; 39 (Suppl); 491.
4. **Mansberger SL**, Williams JM, Sample PA, Zangwill LM, Weinreb RN. Confocal Scanning Laser Ophthalmoscopy in Patients with Large Cup to Disc Ratios and Normal or Abnormal Functional Testing. Invest Ophthalmol Vis Sci. 1999; 40 (Suppl); 657.
5. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the **Ocular Hypertension Treatment Study (OHTS) Group**: Classification of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 1999;40(4):S69.
6. Keltner JL, Johnson CA, Cello KE, Quigg JM, Kass MA, Gordon MO and the **OHTS group**. Severity of the types of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2000;41(4):S84.
7. Feuer WJ, Parrish RK, Wells MC, Schiffman JC, Kass MA, Gordon MO and the **Ocular Hypertension Treatment Study (OHTS) Group**: Reproducibility of reading of optic disc cup/disc ratio in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 1999;40(4):S283.
8. **Mansberger SL**, Spry PGD, Fortune BA, Eke T, Johnson CA, Cioffi GA Cioffi. Frequency Doubling Perimetry and the Detection of Eye Disease in the community. Invest Ophthalmol Vis Sci. 2000; 41 (Suppl): 455.
9. Johnson, CA, Spry, PGD, Cioffi, GA, **Mansberger SL**. Evaluation of a Variety of Visual Function Tests in Ocular Hypertension and Early Glaucoma Patients. Invest Ophthalmol Vis Sci. 2000; 41 (Suppl): 541
10. Brandt JD, Beiser J, Kass MA, Gordon MO, for the **OHTS Study Group**. The relationship of corneal thickness and IOP response to topical β -blocker in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 2001; 42(4): S421.
11. Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, Bandermann SE, Edwards MA, **Ocular Hypertension Study Group**. Visual field technician performance in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2001;42(4): S152.
12. **Mansberger SL**, Johnson, CA, Cioffi, GA, Krishnadas, R, Srinivasan, M, Balamurugan, V, Kim, U, Smith, SD, Wilkins, JH, Gritz, DC. Screening for Glaucoma in India with the Frequency Doubling Perimetry Test. Invest Ophthalmol Vis Sci. 2002; 43 (Suppl): 2154.
13. **Mansberger SL**, Johnson, CA, Butler, WA, Cioffi, GA. Screening with Frequency Doubling Technology Perimetry in a Metropolitan Community. Invest Ophthalmol Vis Sci. 2003; 44 (Suppl): 3413.
14. **Mansberger SL**, Johnson, CA, Accuracy of Ophthalmologists for predicting glaucoma from ocular hypertension. Invest Ophthalmol Vis Sci. 2004
15. Coleman AL, Gordon MO, Beiser JA, Kass MA and the **Ocular Hypertension Treatment Study**. A predictive model for the development of POAG in the Ocular Hypertension Treatment Study excluding pattern standard deviation(PSD) and vertical cup/disc ratio (VC/D). Invest Ophthalmol Vis Sci 2004;45:E-Abstract 955. Presented at ARVO.

16. Keltner JL, Johnson CA, Fan J, Cello KE, Kass MA, Gordon MO **and the Ocular Hypertension Treatment Study (OHTS) group**. Types of visual field abnormalities that subsequently become visual field primary open-angle glaucoma in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2004;45:E-Abstract 2134. Presented at ARVO.
17. Budenz DL, Beiser JA, Piltz JR, Parrish RK, Anderson DR, Gordon MO, Kass MA **and the Ocular Hypertension Treatment Study Group**. Detection and predictive value of optic disc hemorrhages in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 2004;45:E-Abstract 940. Presented at ARVO.
18. Kass MA, Beiser JA, Herman D, Lamping K, Soltau J, Gordon MO **and the Ocular Hypertension Treatment Study Group**. Is there an association of topical ocular hypotensive medication with lens opacification and visual function?: Evidence from the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005; 46: E-Abstract 2448. Presented at ARVO.
19. Keltner JL, Johnson CA, Cello KE, Fan J, Bandermann SE, Kass MA, Gordon MO, Beck RW **and the Ocular Hypertension Treatment Study (OHTS) group**. Visual field quality control in the Ocular Hypertension Treatment Study and in the 10-Year Optic Neuritis Treatment Trial (ONTT) Follow-Up Study. Invest Ophthalmol Vis Sci 2005;46: E-Abstract 3738. Presented at ARVO.
20. **Mansberger SL**, Hughes BA, Gordon MO, Spaner SL, Beiser, JA, Cioffi GA, Kass MA **and the Ocular Hypertension Treatment Study (OHTS) Group**. Comparison of IOP response to topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and whites: The Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005;46: E-Abstract 2449. Presented at ARVO.
21. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz MC, Kass MA, Gordon MO **and the Ocular Hypertension Treatment Study Group**. Test-retest reproducibility of determining optic disc deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005;46: E-Abstract 3630. Presented at ARVO.
22. **Mansberger SL**, Romero FC, Smith NH, Johnson CA, Cioffi GA, Edmunds B, Choi D, Becker T. Causes of Visual Impairment and Common Eye Problems in Northwest American Indian/Alaskan Natives. American Glaucoma Society. March 2005.
23. **Mansberger SL**, Romero FC, Smith NH, Johnson CA, Cioffi GA, Edmunds B, Choi D, Becker T. Causes of Visual Impairment and Common Eye Problems in Northwest American Indian/Alaskan Natives. National Institutes of Health. Native American Research Center for Health. November 2005.
24. Zangwill LM, Weinreb RN, Beiser JA, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Kass MA, Gordon MO **and the OHTS CSLO Ancillary Study Group**. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS. Invest Ophthalmol Vis Sci 46: E-Abstract 3631. Presented at ARVO May 1-6, 2005.
25. **Mansberger SL**, Fortune B, Demirel S, Zhang X, Hood DC, Patterson E, Jamil A, Cioffi GA, Johnson CA. Comparison Between Multifocal Visual Evoked Potentials (mfVEP) and Standard Automated Perimetry (SAP) in High-Risk Ocular Hypertension and Early Glaucoma. ARVO 2006.
26. Nguyen HT, Pikey KP, Gardiner SK, Cioffi GA, **and Mansberger SL**. Variability of HRT Parameters in Contour Line Placement, With and Without the Aid of Stereographic Photographs. ARVO 2006.
27. Cioffi GA **and Mansberger SL**. Comparison Of the Risk Estimates For Converting To Glaucoma With Two Published Risk Calculators. ARVO 2006.
28. McClure TM **and Mansberger SL**. The Effect of Visual Impairment on Vision-Related Quality of Life in American Indian/Alaska Native Populations. ARVO 2006.
29. **Mansberger SL**, Cioffi GA, Choi D, Johnson CA. Screening Tests for Visually Significant Eye Diseases in American Indian/Alaska Native Participants. ARVO 2006.
30. Brandt JD, Beiser JA, Gordon MO, Lin SC, Alexander MY, Kass MA **and the Ocular Hypertension Treatment Study Group**. Time Dependent Changes in Central Corneal Thickness in the Ocular

- Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2006; E-Abstract 4422. Presented at ARVO.
31. Keltner JL, Johnson CA, Cello KE, Fan J, Levine RA, Bandermann SE, Kass MA, Gordon MO, Beck RW and **the Ocular Hypertension Treatment Study Group**. Visual Field Quality Control in the Ocular Hypertension Treatment Study (OHTS) and the Optic Neuritis Treatment Trial (ONTT). Invest Ophthal Vis Sci 2006; E-Abstract 3394. Presented at ARVO.
 32. **Mansberger SL**, Kass M, The OHTS Group, The EGPS Group. OHTS/EGPS: Clinical Significance of Baseline Asymmetry in Predicting the Risk of Developing POAG. Annual Meeting of the American Glaucoma Society. March 2007.
 33. Artes PH, Chauhan BC, Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, and **Ocular Hypertension Treatment Study Group**. Longitudinal and Cross-Sectional Analyses of Visual Field Progression in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007;E-Abstract 4447. Presented at ARVO.
 34. Bandermann SE, Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, and **Ocular Hypertension Treatment Study Group**. A Comparison Of Full Threshold and Swedish Interactive Threshold Algorithms (SITA) Testing procedures in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007;E-Abstract 1643. Presented at ARVO.
 35. Bhorade AM, Wilson BS, Palmberg P, Miller E, Chang RT, Kass MA, Gordon MO, and **Ocular Hypertension Treatment Study Group**. The Predictive Accuracy of the One-Eyed Trial in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007; E-Abstract 5555. Presented at ARVO.
 36. Achtenberg JF, Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the **Ocular Hypertension Treatment Study Group**. Phased transition from traditional data entry to a web-based system. Presented at SCT May 21-24, 2007.
 37. Demirel S and the **Ocular Hypertension Treatment Study Group**. Rates of change of mean deviation in the OHTS. Presented at ARVO, May 6, 2010. Mansberger SL, Nguyen H, Torres R, Demirel S, Fortune BA, Gardiner SK, Cioffi GA, Johnson CA. Patterns of optic disc change in early glaucoma and glaucoma suspect patients. ARVO 2007.
 38. McClure TM, Swanson IL, Becker TM, Coleman AL, Cioffi GA, **Mansberger SL**. Changes in Vision-Related Quality of Life in Native American/Alaska Native Populations After Best-Correction. ARVO 2007.
 39. Demirel S, Fortune BA, Zhang X, Hood DC, Patterson E, Jamil A, **Mansberger SL**, Cioffi GA, Johnson CA. Effect of Recording Duration on Diagnostic Performance of Multifocal Visual Evoked Potentials in High-Risk Ocular Hypertension and Early Glaucoma. ARVO 2007.
 40. Kass MA, Gordon MO and the **Ocular Hypertension Treatment Study Group**. Is a history of diabetes mellitus (DM) protective against developing primary open-angle glaucoma (POAG)? Presented at the American Glaucoma Society, March 7, 2008.
 41. Keltner JL, Johnson CA, Cello KE, Brusini P, Kass MA, Gordon MO and the **Ocular Hypertension Treatment Study Group**. Application of Brusini's Glaucoma Staging System 2 (GSS 2) to glaucomatous visual fields in the Ocular Hypertension Treatment Study. Presented at ARVO, April 27, 2008.
 42. Bhorade AM, Wilson BS, Palmberg P, Miller E, Weinreb R, Kass MA, Gordon MO and the **Ocular Hypertension Treatment Study Group**. Intraocular pressure variability in observation participants in the Ocular Hypertension Treatment Study. Presented at ARVO, April 28, 2008.
 43. Kymes SM, Kass MA, Miller JP, Gordon MO, and the **Ocular Hypertension Treatment Study Group**. The 20-year incidence of primary open-angle glaucoma among people with ocular hypertension – A decision analytic approach. Presented at ARVO, May 1, 2008.
 44. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO and the **Ocular Hypertension Treatment Study Group**. Retinal vein occlusions (RVO) in the Ocular Hypertension Treatment Study. Presented at ARVO, May 1, 2008.

45. Long EF, Dunn D, Gordon MO, the **Ocular Hypertension Treatment Study group**. Close-out manual of procedures for a long-term clinical trial. Presented at the Society for Clinical Trials. May 19, 2008.
46. Gordon MO, Sarli C, Long EF, LaRue C, the **Ocular Hypertension Treatment Study Group**. Assessing the impact of research. Presented at the Society for Clinical Trials, May 20, 2008.
47. Kass MA, Gordon MO, the **Ocular Hypertension Treatment Study Group**. Diabetes and Glaucoma. *Arch Ophthalmol*. 2008;126(5):746-747.
48. **Mansberger SL**, Fallon S, Wong B, Lucas B. Predictive factors for following up with an eye care in those at risk for glaucoma. American Glaucoma Society 2008
49. Mackenzie PJ, Johnson CA, Gritz DC, Krishnadas SR, **Mansberger SL**. Predictive Value of Heidelberg Retinal Tomography and Frequency Doubling Technology Perimetry for Detecting Glaucoma in a Developing Country. ARVO 2008.
50. Pham H, Gritz DC, Krishnadas SR, Johnson CA, **Mansberger SL**. Frequency Doubling Technology Perimetry Repeatability in a Developing Country. ARVO 2008.
51. Demirel S, Fortune BA, Fan J, Levine RA, Torres R, Nguyen H, **Mansberger SL**, Gardiner SK, Cioffi GA, Johnson CA. Predicting Progressive Glaucomatous Optic Neuropathy Using Standard Automated Perimetry. ARVO 2008.
52. Mansberger SL, McClure TM, Swanson IL, Lambert WE, Cioffi GA. Predictive Validity of the Glaucoma Treatment Compliance Assessment Tool. ARVO 2008.
53. O'Leary N, **Mansberger SL**, Twa MD, Fortune BA, Lloyd MJ, Cioffi GA, Johnson CA, Garway-Heath DF, Crabb DP. Glaucomatous Progression in Series of Stereo-Paired Photographs and Heidelberg Retinal Tomography Images. ARVO 2008.
54. McClure TM, Swanson IL, Lambert WE, Cioffi GA, **Mansberger SL**. Psychometric Properties of the Glaucoma Treatment Compliance Assessment Tool. ARVO 2008.
55. Swanson IL, McClure TM, Cioffi GA, Lambert WE, **Mansberger SL**. Content Validity of a Glaucoma Compliance Focus Group. ARVO 2008.
56. Z. Hoffelt, **S.L. Mansberger**, S. Fallon, B. Wong, B. Lucas. Predictive Factors for Following Up With an Eye Care Provider in Those at Risk for Glaucoma. ARVO 2009
57. P.J. Mackenzie, H. Pham, N.G. Stouthidis, **S.L. Mansberger**, S.K. Gardiner, C.F. Burgoyne. Peripapillary HRT Reflectance Changes in Non-Human Primate Experimental Glaucoma. ARVO 2009
58. T.M. McClure, I. Swanson, K. Wooten, T.M. Becker, **S.L. Mansberger**. Proportion of Diabetic Retinopathy Found in Rural and Urban Populations of American Indian/Alaska Natives and Other Ethnicities Using Either a Telemedicine Protocol or Traditional Surveillance Techniques. ARVO 2009.
59. S. Demirel, Z. Hoffelt, C.A. Johnson, **S.L. Mansberger**, G.A. Cioffi. Stability of Central Corneal Thickness (cct) in Individuals With High-risk Ocular Hypertension or Early Glaucoma. ARVO 2009.
60. Gordon MO, Heuer DK, Higginbotham EJ, Parrish RK, Morris PA, Dunn DA, Wilson BS, Kass MA, and the **Ocular Hypertension Treatment Study Group**. Impact of attributing cause of abnormality to POAG on endpoint rate and statistical power in the OHTS. Presented at ARVO, May 2, 2010.
61. Kass MA and the **Ocular Hypertension Treatment Study Group**. Incidence of glaucomatous visual field loss subsequent to initial glaucomatous optic disc deterioration in the OHTS. Presented at ARVO, May 3, 2010.
62. Zangwill L and the **Ocular Hypertension Treatment Study Group**. The rate of topographic optic disc change is faster in eyes developing POAG than in eyes not developing POAG: CSLO Ancillary Study to the OHTS. Presented at ARVO, May 3, 2010.
63. DeMoraes C and the **Ocular Hypertension Treatment Study Group**. Effect of treatment on rates of visual field change in the OHTS. Presented at ARVO, May 3, 2010.
64. Brandt JD and the **Ocular Hypertension Treatment Study Group**. Does Adjusting IOP for central corneal thickness improve accuracy of the prediction model for the development of POAG? Presented at ARVO, May 4, 2010.

65. TM McClure, K Wooten, T. Becker, **SL Mansberger**, 5/2-6/2010, ARVO, Ft. Lauderdale, FL. Abstract, Accepted: Proportion of Progression of Diabetic Eye Disease in Patients Monitored With a Non-Mydriatic Retinal Camera
66. SL Mansberger, K Wooten, T Becker, **SL Mansberger**. Pacific Region Indigenous Doctor Conference, (PriDoc). August 2010. British Columbia, Canada. "Telemedicine to detect diabetic retinopathy in American Indian/Alaskan Natives."
67. **SL Mansberger**, T Zaback, TM Becker. Using Telemedicine to Detect Diabetic Retinopathy in AI/AN and other Ethnicities. Oregon Public Health Association Annual Conference, Corvallis, Oregon. October 2010.
68. **SL Mansberger**, TM Becker. Using Telemedicine to Detect Diabetic Retinopathy in AI/AN and other Ethnicities. American Public Health Association Annual Meeting, Denver, Colorado. November 2010.
69. **SL Mansberger**, MO Gordon, H Jampel, A Bhorade, JD Brandt, B Wilson, MA Kass, and the Ocular Hypertension Treatment Study (OHTS) Group. Change in intraocular pressure after cataract extraction in The Ocular Hypertension Treatment Study (OHTS). American Glaucoma Society, March 2011
70. **SL Mansberger**, KG Gleitsmann, SK Gardiner, CR Sheppler, DJ Moore, TM Becker. Using Telemedicine to Monitor Diabetic Retinopathy in an Underserved Population. Contemporary Northwest Tribal Health Conference, Portland, Oregon. March 2011.
71. **SL Mansberger**, K Gleitsmann, S Gardiner, C Sheppler, D Moore, and T Becker. "Using Telemedicine to Monitor Diabetic Retinopathy in an Underserved Population". Prevention Research Conference, Atlanta, Georgia. April 2011.
72. **SL Mansberger**, K Gleitsmann, S Gardiner, C Sheppler, D Moore, and T Becker. "Using Telemedicine to Monitor Diabetic Retinopathy in an Underserved Population". CDC Translational conference Minneapolis, MN. April 2011.
73. A Alqudah, **SL Mansberger**, S Gardiner, C Blachly, S Demirel. "The association between quality of life and visual field status in glaucoma patients." Presented at ARVO, May 2011
74. **SL Mansberger**, MO Gordon, H Jampel, A Bhorade, JD Brandt, B Wilson, MA Kass, and the Ocular Hypertension Treatment Study (OHTS) Group. Reduction in intraocular pressure after cataract extraction in The Ocular Hypertension Treatment Study (OHTS). American Glaucoma Society, March 2011
75. CR Sheppler, **SL Mansberger**, CL VanAlstine, TM Becker. Compliance with Annual Diabetic Eye Exams Survey: Pilot Study Results. Oregon Public Health Association Annual Meeting, Corvallis, Oregon. October 2011.
76. **SL Mansberger**, KG Gleitsmann, SK Gardiner, CR Sheppler, DJ Moore, TM Becker. The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy in American Indians and Alaska Natives. American Public Health Association Annual Meeting, Washington, D.C. November 2011.
77. Cook, P. F., Fitzgerald, T., **Mansberger, S. L.**, Kammer, J., & Kahook, M. Y. (2012, March). Adherence matters: Relationships between adherence, health, vision, and barriers to care in glaucoma treatment. Poster presentation at the American Glaucoma Society (AGS) conference, New York NY
78. **SL Mansberger**, CR Sheppler, WE Lambert, J. Lapidus, SK Gardiner, TM Becker. Validity of the Compliance with Annual Diabetic Eye Exams Survey (CADEES). Society of Behavioral Medicine Annual Meeting, New Orleans, Louisiana. April 2012.
79. VanAlstine C, Kymes SM, StWalley D, Sheppler CR, **Mansberger SL**. Cost-Effectiveness of Telemedicine Screening for Diabetic Retinopathy. Presented at ARVO, May 2012
80. Shepper CR, Lambert WE, VanAlstine CL, **Mansberger SL**. Compliance with Annual Diabetic Eye Exams Survey (CADEES): Preliminary Results. Presented at ARVO, May 2012
81. Takusagawa HL, Sheppler CR, VanAlstine C, Gardiner SK, **Mansberger SL**. Prevalence Of Glaucomatous Optic Neuropathy In A Telemedicine Population. Presented at ARVO, May 2012

82. **SL Mansberger**, CR Sheppler, CL VanAlstine, TM Becker. Using Telemedicine to Screen for Diabetic Retinopathy in Primary Care Clinics. Native Health Research Conference, Seattle, Washington. July 2012.
83. TM Becker, **SL Mansberger**, KG Gleitsmann, SK Gardiner, CR Sheppler, DJ Moore. The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy in American Indians and Alaska Natives. Advancing Native Health and Wellness Conference, Anchorage, Alaska. August 2012.
84. **SL Mansberger**, CR Sheppler, CL VanAlstine, SK Gardiner, K Wooten, TM Becker. The Long-Term Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy. American Public Health Association 140th Annual Meeting, San Francisco, California. October 2012.
85. CR Sheppler, **SL Mansberger**, CL VanAlstine. Demographic and Health Belief Variables Associated with Adherence to Annual Diabetic Eye Exams. American Public Health Association Annual Meeting, San Francisco, California. October 2012.
86. T Zaback, WE Lambert, M Dignan, **SL Mansberger**, TM Becker. Summative Evaluation of a Tribal Telemedicine Project. American Public Health Association 140th Annual Meeting, San Francisco, California. October 2012.
87. Koenigsman H, Kammer J, Kahook M, Cook P, Mansberger SL. Glaucoma Treatment Compliance Assessment Tool as predictive tool for medication adherence. Presented at American Glaucoma Society Annual meeting, March 2013
88. **SL Mansberger**, SK Gardiner, S Demirel, TM Becker. Long-term comparative effectiveness of telemedicine to detect diabetic retinopathy. Telehealth Alliance of Oregon Annual Meeting, Springfield, Oregon. April 2013.
89. CR Sheppler, **SL Mansberger**. Qualitative analysis of implementing a telemedicine program to provide annual diabetic retinopathy screening exams at an internal medicine clinic: Benefits, barriers, and future directions. Telehealth Alliance of Oregon Annual Meeting, Springfield, Oregon. April 2013.
90. **SL Mansberger**, SK Gardiner, S Demirel, TM Becker. Long-term comparative effectiveness of telemedicine to detect diabetic retinopathy. Association for Research in Vision and Ophthalmology, Seattle, Washington. May 2013.
91. GT Barker, PF Cook, MY Kahook, JA Kammer, **SL Mansberger**. The Glaucoma Treatment Compliance Assessment Tool (GTCAT) has an organizational structure consistent with the Health Belief Model. The Association for Research in Vision and Ophthalmology Annual Conference, Seattle, WA. May 2013.
92. RM Kinast, GT Barker, SH Day, **SL Mansberger**. Patient satisfaction within online reviews of ophthalmologists evaluated by contextual analysis. American Academy of Ophthalmology. New Orleans, LA. November 2013.
93. CF Burgoyne, R Ren, H Koenigsman, RM Kinast, J Reynaud, H Yang, SK Gardiner, **SL Mansberger**, S Demirel, B Fortune. Variability of glaucoma specialists rim width estimates and their accuracy relative to colocalized spectral domain optical coherence tomography (SDOCT). American Glaucoma Society. Washington, DC. March 2014
94. SK Gardiner, WH Swanson, D Goren, **SL Mansberger**, S Demirel. Assessment of the reliability of standard automated perimetry in regions of glaucomatous damage. American Glaucoma Society. Washington, DC. March 2014
95. I Estrovich, **SL Mansberger**, YI Chu. Intraocular pressure assessment in keratoprosthesis eyes: comparison of tono-pen XL and schiottz tonometer. American Glaucoma Society. Washington, DC. March 2014
96. RM Kinast, GT Barker, KK Akula, A DeBarber, ER Whitson, **SL Mansberger**. The degradation of mitomycin under various storage methods. American Glaucoma Society. Washington, DC. March 2014
97. RM Kinast, GT Barker, SH Day, **SL Mansberger**. Online reviews of ophthalmologists compared by subspecialty. American Society of Cataract and refractive surgery. Boston, MA. April 2014

98. T Navratil, A Garcia, J Tully, L Trevino, M Hunter, D Stoltz, R Robeson, B Maynor, IK Ahmed, DL Budenz, RA Lewis, **SL Mansberger**, BC Gilger, and B Yerxa. Preclinical Evaluation of ENV515-1 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action. ARVO. Orlando, FL. May 2014.
99. **SL Mansberger**, GT Barker, PF Cook, MY Kahook, JA Kammer. The Glaucoma Treatment Compliance Assessment Tool (GTCAT) has an organizational structure consistent with the Health Belief Model. The American Ophthalmological Society, New York, NY. June 2014.
100. SA Menda, **SL Mansberger**, GL Barker, SK Gardiner, S Demirel. Changes in Vision-Related Quality of Life in Patients with Early and Suspected Glaucoma . American Glaucoma Society, Coronado, CA. March 2015
101. RM Kinast, KK Akula, GT Barker, **SL Mansberger**, SK Gardiner, E Whitson, A DeBarber. Concentration Accuracy of Compounded Mitomycin C for Ophthalmic Surgery. American Glaucoma Society, Coronado, CA. March 2015.
102. S Demirel, B Fortune, **SL Mansberger**, SA Gardiner. Age as a predictor of future rate of visual field change in glaucoma: Traditional statistics and tree-based modeling. Association for Research in Vision and Ophthalmology. Denver CO. May 2015
103. S Menda, B Fortune, **SL Mansberger**, S Gardiner, S Demirel. The effect of manually refining automated image segmentations on retinal nerve fiber layer thickness measurements from optical coherence tomography (OCT) scans. Association for Research in Vision and Ophthalmology. Denver CO. May 2015
104. D Park, **SL Mansberger**. Prevalence of Common Eye Diseases in Diabetic Patients Followed by Telemedicine. Association for Research in Vision and Ophthalmology. Denver CO. May 2015
105. T Navratil, A Garcia, R Verhoeven, L Trevino, B Gilger, **SL Mansberger**, D Budenz, I Ahmed, R Lewis, B Yerxa. Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study. Association for Research in Vision and Ophthalmology. Denver CO. May 2015
106. **SL Mansberger**, T Navratil, TR Walters, BE Silverstein, SM Silverstein MD, JH Peace, HB DuBiner, T Durham, VC Conley, JP Berdahl, FW Price, IK Ahmed, JS Pepose, BR Yerxa, RM Schiffman First-Time-in-Human Safety and Efficacy Evaluation of Intracameral ENV515 Travoprost XR in Glaucoma Patients. American Academy of Ophthalmology. Las Vegas, NV. October 2015
107. Peripapillary Retinoschisis in Glaucomatous and Suspect Eyes. Kelly Ma, Shaban Demirel, Stuart Gardiner, Brad Fortune, **SL Mansberger**. ARVO. Seattle, WA. May 2016
108. Completed 28-Day and Ongoing 12-Month Safety and Efficacy Evaluation of ENV515 (travoprost) Intracameral Implant in Phase 2 Study. Thomas Walters, Tomas Navratil, Stacey Pittman, Virginia Conley, Leo Trevino, Bruce Silverstein, Michael Depenbusch, **SL Mansberger**, Rhett Schiffman. ARVO. Seattle, WA. May 2016
109. Comparing the Psychometric Properties of the Original and Short Versions of the Glaucoma Treatment Compliance Assessment Tool. Gordon Barker, **SL Mansberger**. ARVO. Seattle, WA. May 2016
110. Errors In Retinal Nerve Fiber Layer Thickness Measurements Using Automated Segmentation Of Optical Coherence Tomography. **SL Mansberger**, Shivali Menda, Brad Fortune, Stuart K Gardiner, Shaban Demirel. AOS. Colorado Springs, CO. June 2016
111. Interim 3-Month Safety and Efficacy Evaluation of Low-Dose Intracameral ENV515 Travoprost XR in 12-Month Study in Glaucoma Patients. Thomas R Walters MD, Tomas Navratil PHD, Virginia Conley, MBA, Leo Trevino, BS, PHD, Bruce E Silverstein MD, Iqbal K Ahmed MD, **Steven L Mansberger MD MPH**, Benjamin R Yerxa PhD, Rhett M Schiffman MD. Chicago, IL. October 2016.
112. Interim Analysis Of Low Dose ENV515 Travoprost XR With 9 Month Duration And IOP-Lowering Effects Of Pre-Study PGA's And In-Study Timolol. **Mansberger SL**; Navratil TT; Ahmed IK; Walters TR; Yerxa B; Conley JS. SL Mansberger. American Glaucoma Society. Coronado, CA. March 2017

113. Detection of Functional Change Using Cluster Trend Analysis in Glaucoma. Stuart K. Gardiner; **Steven L. Mansberger**; Shaban Demirel. Invest. Ophthalmol. Vis. Sci.. 2017; 58(6):BIO180-BIO190. doi: 10.1167/iovs.17-21562.
114. Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy. Tomas Navratil; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Akshay Nadkarni; Leo Trevino; Benjamin R Yerxa; Michael Depenbusch; Tracey Knox; Iqbal Ahmad; Thomas R Walters; **Steven L Mansberger**. Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2108.
115. Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose. **Steven L Mansberger**; Jinny Conley; Rozemarijn S Verhoeven; Kristin Blackwell; Michael Depenbusch; Tracey Knox; Thomas R Walters; Iqbal Ahmad; Benjamin R Yerxa; Tomas Navratil. Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2110.
116. Peripapillary retinoschisis in glaucoma: association with progression and OCT signs of Muller cell involvement. Fortune B, Ma KN, Gardine SK, Demirel S, **Mansberger SL**. American Ophthalmological Society 2018
117. Analysis and prediction of total visit length and provider interaction times using electronic health record (EHR) data and machine learning. David Sebastian Sanders, Isaac Goldstein, Michelle Hribar, Aiyin Chen, Wei-Chun Lin, Steven L. Mansberger, Michael F. Chiang. ARVO 2019.
118. Predictors of Receiving Annual Dilated Eye Examinations Among US Patients with Diabetes. Sarah Eppley, Eugene Lowry, **Steven L. Mansberger**, Saras Ramanathan. ARVO 2019.
119. Optic nerve head prelaminar tissue schisis: a sign of glaucomatous deformation? Eugene Lowry, **Steven L. Mansberger**, Stuart Keith Gardiner, Hongli Yang, Facundo Gregorio Sanchez, David Sebastian Sanders, Shaban Demirel, Claude F. Burgoyne, Brad Fortune. ARVO 2019.
120. Lamina cribrosa depth and mean cup depth changes in the setting of trabeculectomy in patients with open angle glaucoma. Facundo Gregorio Sanchez, David Sebastian Sanders, Brad Fortune, Stuart Keith Gardiner, Juan Reynaud, Eugene Lowry, **Steven L. Mansberger**. ARVO 2019.
121. Improved Detection of Optical Coherence Tomography (OCT) Structural Abnormality in Glaucoma (GL) with Combined Sectoral Rim and Retinal Nerve Fiber Layer (RNFL) Criteria. Hongli Yang, , Haomin Luo, , Christy A. Hardin, , Cindy Albert, Jayme Vianna, Glen Sharpe, Juan Reynaud, , Shaban Demirel, **Steven L. Mansberger**, Brad Fortune, Stuart Keith Gardiner, Balwantray C. Chauhan, Claude F. Burgoyne. ARVO 2019.
122. Detecting functional change using permutation tests on overlapping clusters of visual field locations. Stuart Keith Gardiner, Shaban Demirel, **Steven L. Mansberger**, Cindy Albert. ARVO 2019.
123. Predicting adherence with the Glaucoma Treatment Compliance Assessment Tool – Short (GTCAT-S). FG Sanchez, MD; **SL Mansberger**; PA Newman-Casey. American Academy of Ophthalmology 2019.
124. NCX 470, a Nitric Oxide Donating Bimatoprost Analog, Demonstrates Superiority to Latanoprost in Phase 2 Dolomites Clinical Trial”. D Wirta, P Hartman, TR Walters, K Jong, H DuBiner, H DuBiner, K Lopez, B Duquesroix, A Kothe, J Boyer, **SL Mansberger**, RD Fechtner, DL Budenz, T Navratil. American Glaucoma Society 2020
125. “Intraocular Pressure Spikes after Cataract Surgery in Glaucoma and Non-glaucoma patients”. FG Sanchez and **SL Mansberger**. American Glaucoma Society 2020
126. NCX 470 for IOP-lowering: Results of the Phase 2 Dolomites Trial. Walters TR, **Mansberger SL**, DuBiner, H, Budenz D, Fechtner R, Navratil T. Association for Research in Vision and Ophthalmology
127. NCX 470 Ophthalmic Solution for IOP Lowering: Results of the Phase 2 Dolomites Trial. Walters TR, David L Wirta DL, Hartman PJ, Jong KY, DuBiner HB, DuBiner H, Lopez K, Duquesroix B, Kothe AC, **Mansberger SL**, Fechtner RD, Budenz DL. American Academy of Ophthalmology Nov 2020
128. Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction Robert M Kinast, Facundo G Sanchez., Yungtai Kung, Stuart K Gardiner, Claude F Burgoyne, Emmett T Cunningham, Jr, Jack P Rees, Emily P Jones, **SL Mansberger**. American Glaucoma Society, March 2021

129. Cataract Surgery Lowers Intraocular Pressure and Medication Use in the Treatment Group in the Ocular Hypertension Treatment Study (OHTS). **SL Mansberger**, SK Gardiner, and P Rumulu. American Glaucoma Society. March 2021
130. Rate of Bimatoprost Implant Biodegradation in the Phase 3 ARTEMIS Studies. Jacob W. Brubaker, Steven L. Mansberger, James D. Branch, Kevin Wang, Michael R. Robinson, Mitra Sehi. Association for Research in Vision and Ophthalmology 2021
131. Biometric parameters can predict IOP change and IOP spikes after cataract surgery in glaucoma patients. Facundo Gregorio Sanchez; Jack Rees; Stuart Keith Gardiner; Steven L Mansberger. Association for Research in Vision and Ophthalmology 2021. Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3396. doi:
132. Rate of bimatoprost implant biodegradation in the phase 3 ARTEMIS studies Jacob W. Brubaker; Steven L Mansberger; James D. Branch; Kevin Wang; Michael R Robinson; Mitra Sehi Investigative Ophthalmology & Visual Science June 2021, Vol.62, 627
133. Clinicians' Use of Quantitative Information when Assessing Structural Progression in Glaucoma Stuart Keith Gardiner; Robert Kinast; Teresa C Chen; Nicholas G Strouthidis; C Gustavo De Moraes; Kouros Nouri-Mahdavi; Jonathan S. Myers; Jin Wook Jeoung; John Lind; Lindsay Anne Rhodes; Donald L Budenz; Steven L Mansberger. Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1858.
134. Diagnostic accuracy of inner retinal layer thickness and reflectance intensity measurements assessed in posterior pole OCT scans of healthy and glaucomatous eyes Hongli Yang; Juan Reynaud; Glen P Sharpe; Dawn Jennings; Cindy Albert; Galen Williams; Xiue Jiang; Shaban Demirel; Steven L Mansberger; Jayme R Vianna; Marcelo Nicolela; Balwantray C Chauhan; Claude F Burgoyne; Stuart Keith Gardiner; Brad Fortune. Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1836
135. Clinicians' Use of Global Indices when Assessing Functional Progression in Glaucoma Steven L Mansberger; Robert Kinast; C Gustavo De Moraes; Donald L Budenz; Jin Wook Jeoung; John Lind; Jonathan S. Myers; Kouros Nouri-Mahdavi; Lindsay Anne Rhodes; Nicholas G Strouthidis; Teresa C Chen; Stuart Keith Gardiner. Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1842. doi:
136. Optic Nerve Head Cavernous Voids in Glaucoma Suspect and Glaucoma Patients Bennett Hong; Robert Kinast; Brad Fortune; Claude F Burgoyne; Steven L Mansberger Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3394. doi:
137. OCT segmentation errors of Minimum Rim Width (MRW) and Retinal Nerve Fiber Layer Thickness (RNFLT) in glaucoma subjects Jack Rees; Facundo Gregorio Sanchez; Hongli Yang; Stuart Keith Gardiner; Steven L Mansberger Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1823. doi:
138. Geospatial analytics and blindness within rural and urban counties. FG Sanchez, SK Gardiner, S Demirel; JP Rees, SL Mansberger. American Ophthalmology Society. May 2021.
139. Gardiner SK and SL Mansberger. Using Moving instead of Static Stimuli to Extend the Dynamic Range of Perimetry. ARVO 2022
140. Patient Reported Outcome Measures while using a device to objectively measure eye drop adherence. S.L. Mansberger, F.G. Sanchez, J.P. Rees, S.K. Gardiner, V. Klei, J. Duvdevany, M.L. Kobak, R.M. Kinast. ARVO 2022
141. Eye Drop Adherence With an Eye Drop Bottle Cap Monitor. RM Kinast, FG Sanchez, JP Rees, K Yeh, SK Gardiner, J Dawes, ML Johnston, J David Porter, V Klei, SL Mansberger. American Glaucoma Society. Austin, TX. 2023
142. NCX 470, a Nitric Oxide Donating Bimatoprost, Demonstrates Non-inferiority to Latanoprost in Phase 3 Mont Blanc Clinical Trial RD Fechtner, SL Mansberger, J Branch, J Mulaney, S Ziebell and K Lopez. American Glaucoma Society. Austin, TX. 2023
143. NCX 470, a Nitric Oxide Donating Bimatoprost versus Latanoprost Has Greater Proportion of Subjects Achieving ≥ 10 mmHg IOP Decrease in Phase 3 Trial. Robert Fechtner, Steven Mansberger, Krisi Lopez. World Glaucoma Congress. Rome, IT. 2023
144. NCX 470, a Nitric Oxide Donating Bimatoprost Compared with Latanoprost - Adaptive Design Period Results from the Phase 3 Mont Blanc Clinical Trial. Steven Mansberger, Robert Fechtner, Krisi Lopez. World Glaucoma Congress. Rome, IT. 2023

145. Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Naïve Patients SL Mansberger D Hubatsch. American Glaucoma Society. Huntington Beach, CA. 2024
146. Retinal vascular resistance increases, then later decreases, as glaucoma progresses. SK Gardiner, B Fortune¹, SL Mansberger, G Cull. Associate for Research in Vision and Ophthalmology. Seattle 2024.
147. Patient reported outcome measures about neurosensory loss from the 80 Years and Older Vision & Hearing Important Persons Project (80VIP). MT Shaw, J Rees, SL Mansberger. Associate for Research in Vision and Ophthalmology. Seattle 2024.
148. Systemic pulse waveform parameters associated with vascular stiffness can predict the rate of functional progression in glaucoma and glaucoma suspects. H Yang, G Cull, M Yang, SL Mansberger, B Fortune, SK Gardiner. Associate for Research in Vision and Ophthalmology. Seattle 2024.

Published Manuscripts:

1. Harris A, Caldemeyer KS, **Mansberger SL**, Martin BJ. Alpha-adrenergic agonists' effects on ocular hemodynamics. *J Glaucoma*. 1995 Feb;4 Suppl 1:S19-23. PMID: 19920643.
2. Orgul S, **Mansberger S**, Bacon DR, Van Buskirk EM, Cioffi GA. Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits. *Am J Ophthalmol*. 1995 Oct;120(4):441-7. PMID: 7573301.
3. Cioffi GA, Van Buskirk EM, **Mansberger S**, Bacon DR, Orgul S. Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits: author reply [letter]. *Am J Ophthalmol*. 1996 Apr;121(4):456-457.
4. Liu JH, Kripke DF, Hoffman RE, Twa MD, Loving RT, Rex KM, Lee BL, **Mansberger SL**, Weinreb RN. Elevation of human intraocular pressure at night under moderate illumination. *Invest Ophthalmol*. 1999; 40(10): 2439-42. PMID: 10549652.
5. **Mansberger SL**, Sample PA, Zangwill L, Weinreb RN. Achromatic and Short Wavelength Automated Perimetry in Patients with Glaucomatous Large Cups. *Arch Ophthalmol*. 1999; 117:1473-1477. PMID: 10565515.
6. Liu JH, Kripke DF, Twa MD, Hoffman RE, **Mansberger SL**, Rex KM, Girkin CA, Weinreb RN. Twenty-Four-Hour pattern of Intraocular pressure in the aging population. *Invest Ophthalmol Vis Sci*. 1999 Nov;40(12):2912-7. PMID: 10549652
7. Keltner, J.L., C.A. Johnson, et al. "Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study, Ocular Hypertension Treatment Study Group." *Arch Ophthalmol*. 2000. 118(9): 1187-94. PMID: 10980763.
8. Gordon, M.O., M.A. Kass, and the **Ocular Hypertension Treatment Study (OHTS) Group**. "The Ocular hypertension Treatment Study: design and baseline description of the participants." *Arch Ophthalmol* 2000;**117**(5): 573-83. PMID: 10326953.
9. **Mansberger SL**, Cioffi GA. Eyelash Formation Secondary to Latanoprost in a Patient with Alopecia. *Arch Ophthalmol*. 2000; 118: 718-719. PMID: 10815168.
10. Kwon YH, **Mansberger SL**, Cioffi GA. Ganglion Cell Death in Glaucoma: Mechanisms and Neuroprotective Strategies. *Ophthalmology Clinics of North America*. Sept 2000; 13(3): 465-479.
11. Cioffi GA, **Mansberger SL**, Spry PGD, Johnson CA, Van Buskirk EM. Frequency Doubling Perimetry and the Detection of Eye Disease in the Community. *Transactions of the American Ophthalmology Society*. 2000; 98: 195-202. PMID: 11190023.
12. Brandt, J.D., J.A. Beiser, and the **Ocular Hypertension Treatment Study (OHTS) Group**. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS)." *Ophthalmology*. 2001. 108(10): 1779-88. PMID: 11581049.

13. **Mansberger SL**, Passo MS, Schalock PI, Cioffi, GA. The predictive value of a one-day, one-eyed trial on the one-month ocular hypotensive response of latanoprost 0.005%. *Am J Ophthalmol.* 2001; 132:869-871. PMID: 11730650
14. **Mansberger SL**. Management of Iris Melanoma with Secondary Glaucoma. *J Glaucoma.* 2002. 11:71-74.
15. Gordon, MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA; the **Ocular Hypertension Treatment Study (OHTS) Group**. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002 June;120(6):714-20; discussion 829-30. PMID: 12049575
16. Johnson, C.A., J.L. Keltner, and the **Ocular Hypertension Treatment Study (OHTS) Group**. Baseline visual field characteristics in the ocular hypertension treatment study." *Ophthalmology.* 2002 109(3): 432-7.
17. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO; the **Ocular Hypertension Treatment Study Group**. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002 Jun;120(6):701-13; discussion 829-30. PMID: 12049574
18. **Mansberger SL**, Passo MS, Schalock PI, Cioffi GA. The predictive value of a one-day, one-eyed trial on the one-month ocular hypotensive response of latanoprost 0.005%. Letter. *Am J Ophthalmol.* 2002; 134:150.
19. **Mansberger SL**. Screening in India with the Frequency Doubling Technology Perimetry test. Masters of Public Health thesis. Oregon Health Science University Department of Public Health and Preventive Medicine. 2002
20. Keltner, J.L., C.A. Johnson, and the **Ocular Hypertension Treatment Study (OHTS) Group**. "Classification of visual field abnormalities in the ocular hypertension treatment study." *Arch Ophthalmol.* 2003 **121**(5): 643-50. PMID: 12742841.
21. **Mansberger SL**, Zangwill LM, Sample PA, Choi D, Weinreb RN. The relationship of optic disc topography and visual function in eyes with large cup to disc ratio. *Am J Ophthalmol.* 2003; 136: 888-894. PMID: 14597041
22. Fortune B, Goh K, Demirel S, Novitsky K, **Mansberger SL**, Johnson CA and Cioffi GA: Detection of glaucomatous visual field loss using multifocal VEP. *Perimetry Update 2002/2003* (Henson and Wall, eds), The Hague: Kugler Publications, 2004, pp 251-260.
23. Ennis FA, Blachly C, Cioffi GA, **Mansberger SL** and Johnson CA: The effect of contour-line drawing criteria on optic disc parameters as measured with the HRT. *Perimetry Update 2002/2003* (Henson and Wall, eds), The Hague: Kugler Publications, 2004, pp 329-330.
24. Brandt, J.D., J.A. Beiser, and the **Ocular Hypertension Treatment Study (OHTS) Group**. "Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study." *Am J Ophthalmol.* 2004. 138(5): 717-22. PMID: 15531304.
25. Higginbotham, E.J., M.O. Gordon, and the **Ocular Hypertension Treatment Study (OHTS) Group**. "The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals." *Arch Ophthalmol.* 2004 122(6): 813-20. PMID: 15197055
26. **Mansberger SL**. A risk calculator to determine the probability of glaucoma. *Journal of Glaucoma.* 2004. 13: 345-47. PMID: 15226665.
27. Zangwill, L.M., R.N. Weinreb, and the **Ocular Hypertension Treatment Study (OHTS) Group**. "Racial differences in optic disc topography: baseline results from the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study." *Arch Ophthalmol.* 2004 122(1): 22-8. PMID: 14718290.
28. Kass MA, Gordon MO, Kymes SM; the **Ocular Hypertension Treatment Study (OHTS) Group**. Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. *Arch Ophthalmol.* 2005 July;123(7):1021-2. PMID: 16009857.

29. Spry PGD, Johnson CA, **Mansberger SL**, Cioffi GA. Psychophysical investigation of ganglion cell loss in early glaucoma. *Journal of Glaucoma*. 2005. 14(1): 11-19. PMID: 15650598.
30. **Mansberger SL**. Management of hypotony after needling revision of an encapsulated bleb. *Journal of Glaucoma*. 2005. 14(4). 299-301.
31. **Mansberger SL**, Johnson CA, Cioffi GA, Choi D, Krishnadas SR, Srinivasan M, Balamurugan V, Kim U, Smith SD, Wilkins JH, Gritz DC. Predictive Value of Frequency Doubling Technology perimetry for detecting glaucoma in a developing country. *Journal of Glaucoma*. 2005. 14(2): 128-134. PMID: 15741814.
32. **Mansberger SL**, Romero FC, Smith NH, Johnson CA, Cioffi GA, Edmunds B, Choi D, Becker TM. Causes of Visual Impairment and Common Eye Problems in Northwest American Indians and Alaskan Natives. *American Journal of Public Health*. 2005. 95(5): 881-6. PMID: 15855469.
33. **Mansberger SL**, Demeril S. Early Detection of Glaucomatous Visual Field Loss: the Why, What, Where, and How. *Clinics of North America*. September 2005. 18(3):365-374. PMID: 16054994
34. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO; the **Ocular Hypertension Treatment Study Group**. Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol*. 2005 Sep;123(9):1188-97. PMID: 16157798
35. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vandenbroucke R, Kass MA, Gordon MO, **the Ocular Hypertension Treatment Group**: Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders. *Am J Ophthalmol* 2005;140:762-64. PMID:16226544.
36. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the **Ocular Hypertension Treatment Study Group (OHTS)**. Normal Visual Field test results following glaucomatous visual field endpoints in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2005;123:1201-06. PMID:1828122.
37. **Mansberger SL**, Patterson E. Risk Calculators: Evidence-based care of ocular hypertension and glaucoma patients. In: Grehn F, Stamper R, editors. *Glaucoma (Essentials in Ophthalmology)*. New York: Springer; 2006. p. 36-46.
38. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the **Ocular Hypertension Treatment Study (OHTS) Group**. Management of Ocular Hypertension: A cost-Effectiveness Approach from the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 2006;141:997-1008. PMID:1775049.
39. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the **Ocular Hypertension Treatment Study (OHTS) Group**. Asymmetries and Visual Field Summaries as Predictors of Glaucoma in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 2006;47:3896-3903. PMID:1995656.
40. Keltner, J.L., C.A. Johnson, and the **Ocular Hypertension Treatment Study Group**. The association between glaucomatous visual fields and optic nerve head features in Ocular Hypertension Treatment Study." *Ophthalmology*. 2006. 113(9): 1603-12. PMID: 18091452
41. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA, and the **Ocular Hypertension Treatment Study (OHTS) Group**. Topical Ocular Hypotensive Medication and Lens Opacification: Evidence from the Ocular Hypertension Treatment Study (OHTS). *Am J Ophthalmol* 2006;142:800-12. PMID:1976472.
42. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon MO, Kass MA and the **Ocular Hypertension Treatment Study (OHTS) Group**. Detection and Prognostic Significance of Optic Disc Hemorrhages During the Ocular Hypertension Treatment Study. *Ophthalmology* 2006;113:2137-43. PMID:1995568.
43. The **Ocular Hypertension Treatment Study (OHTS) Group** and the European Glaucoma Prevention Study (EGPS) Group. A Validated Prediction Model for the Development of Primary

- Open-Angle Glaucoma in Individuals with Ocular Hypertension. *Ophthalmology* 2007;114:10-19. PMID:1995665.
44. Torres R, Nguyen H, **Mansberger SL**. Glaucoma: the sneak thief of sight. *Federal Practitioner*. February 2006. 23(supplement 1): 9-15.
 45. **Mansberger SL**. Normal-tension glaucoma in American Indians/Alaska Natives: a sheep in wolf's clothing. *Glaucoma Today*. March/April 2006. 4(2): 12-14.
 46. **Mansberger SL** and Cioffi GA. The Probability of Glaucoma from Ocular Hypertension determined by Ophthalmologists in comparison to a Risk Calculator. *J Glaucoma*. 2006 Oct;15(5):426-31. PMID: 16988606.
 47. Fortune B, Demirel S, Zhang X, Hood DC, Patterson E, Jamil A, **Mansberger SL**, Cioffi GA, Johnson CA.. Comparing multifocal VEP and standard automated perimetry in high-risk ocular hypertension and early glaucoma. *Invest Ophthalmol Vis Sci*. 2007 Mar;48(3):1173-80. PMID: 18414101.
 48. **Mansberger SL**, Wilson DA. Ocular hypotony. *Roy and Fraunfelder's Current Ocular Therapy 6th Edition*. Saunders. July 2007.
 49. Netland PA, **Mansberger SL**, Lin S. Uncontrolled Intraocular Pressure After Endoscopic Cyclophotocoagulation. *Journal of Glaucoma*. 2007 Mar;16(2):265-267. PMID: 17473744.
 50. **Mansberger SL**, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA. Comparison of Initial IOP Response to Topical Beta-Adrenergic Antagonists and Prostaglandin Analogues in African Americans and Whites in the Ocular Hypertension Treatment Study (OHTS). *Archives of Ophthalmology*. Apr 2007; 125(4):454-9. PMID: 17420364.
 51. **Mansberger SL**, Edmunds B, Johnson CA, Kent K, Cioffi GA. Community visual field screening: prevalence of follow-up and factors associated with follow-up of participants with abnormal Frequency Doubling Perimetry Technology results. *Ophthalmic Epidemiology*, 14:1-7. May-Jun 2007. PMID: 17613848.
 52. **Mansberger SL**, Johnson CA, Cioffi GA. The results of screening frequency doubling technology perimetry in different locations of the community. *J Glaucoma*. 2007 Jan;16(1):73-80. PMID: 17224754.
 53. **Mansberger SL**, Lin S, Netland PA. "Uncontrolled Intraocular Pressure After Endoscopic Cyclophotocoagulation." Letter. Mar;16(2):265-7. 2007.
 54. Medeiros FA, Thomas R, **Mansberger SL**, Gupta N, Weinreb RN, Vitale S. "Clinical Trials and Intraocular Pressure." In: Weinreb RN, Brandt JD, Garway-Heath DF, Medeiros FA, editors. *Intraocular pressure*. The Hague, Netherlands: Kugler Publications; 2007. p. 105-20.
 55. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon MO and the **Ocular Hypertension Treatment Study (OHTS) Group**. Visual Field quality control in the Ocular Hypertension Treatment Study (OHTS). *J Glaucoma*. *J Glaucoma* 2007;16:665-9. PMID:18091452.
 56. Kass MA, Gordon MO, for the **Ocular Hypertension Treatment Study Group**. Diabetes and Glaucoma. *Arch Ophthalmol* 2008;126(5):746-a-7. PMID: 18474807.
 57. Gordon MO, Beiser JA, Kass MA for the **Ocular Hypertension Treatment Study Group**. Is a History of Diabetes Mellitus Protective Against Developing Primary Open-Angle Glaucoma? *Arch Ophthalmol* 2008;126:280-1. PMID:18268230.
 58. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA and the **Ocular Hypertension Treatment Study Group**. Changes in Central Corneal Thickness Over Time: The Ocular Hypertension Treatment Study. *Ophthalmology* 2008;115:1550-1556. PMID:18378313.
 59. Coleman A, **Mansberger SL**, Wilson R. Chapter 36: Epidemiology of Primary Open Angle Glaucoma. Book chapter: *Albert & Jakobiec's Principles and Practice of Ophthalmology*, 3rd Edition. Elsevier. 2008.
 60. Patterson E, Ng J, Jamil A, Cioffi GA, **Mansberger SL**. Late-onset proptosis with Baerveldt glaucoma implants. *Br J Ophthalmol*. 2008 Apr;92(4):580-2. PMID: 18055571.

61. Torres RJ, Patterson E, Edmunds B, Becker T, Cioffi GA, **Mansberger SL**. Central Corneal Thickness in Northwestern American/Alaskan Natives and Comparison to White and African Americans. *Am J Ophthalmol*. Nov; 146(5): 747-51. 2008. PMID: 18672219.
62. Fortune B, Zhang X, Hood DC, Demirel S, Patterson E, Jamil A, **Mansberger SL**, Cioffi GA, and Johnson CA. Effect of Recording Duration on Diagnostic Performance of Multifocal Visual Evoked Potentials in High-Risk Ocular Hypertension and Early Glaucoma. *J Glaucoma*. 2008 Apr-May;17(3):175-82. PMID: 18414101.
63. **Mansberger SL**. "Which glaucoma medications should be used as initial therapy?" *Curbside Consultations in Glaucoma: 49 clinical questions*. p135-138. Book Chapter. Editors: Heuer DK, Gedde SJ, Lewis RA. Thorofare, NJ: SLACK, 2008:xix, 247 p..
64. Pham H, **Mansberger SL**, Brandt J. "Argon Laser Trabeculoplasty: Still the Gold Standard." *Argon laser trabeculoplasty versus selective laser trabeculoplasty*. *Surv Ophthalmol*. 2008 Nov-Dec;53(6):641-6. PMID: 9026324.
65. **Mansberger SL**, Medeiros FA, Gordon M. "Diagnostic Tools for Calculation of Glaucoma Risk". *Surv Ophthalmol*. 2008 Nov;53 Suppl1:S11-6. Review. PMID: 19038619.
66. Bhorade AM, Gordon MO, Wilson B, Weinrab RN, Kass MA and the **Ocular Hypertension Treatment Study Group**. Variability of Intraocular Pressure Measurements in Observation Participants in the Ocular Hypertension Treatment Study. *Ophthalmology* 2009;116:717-724. NIHMS ID:159280.
67. Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, and the **Ocular Hypertension Treatment Study (OHTS) Group**. Delaying Treatment of Ocular Hypertension. *Archives of Ophthalmology* 2010; 128(3):276-287. PMID: 20212196.
68. Barnett EM, Fantin A, Wilson BS, and the **Ocular Hypertension Treatment Study (OHTS) Group**. The Incidence of Retinal Vein Occlusion in the Ocular Hypertension Treatment Study. *Ophthalmology* 2010; 117(3):484-8. PMID: 20031222.
69. Demirel S, Fortune B, Fan J, Levine RA, Torres R, Nguyen H, **Mansberger SL**, Gardiner SK, Cioffi GA, Johnson CA. "Predicting progressive glaucomatous optic neuropathy using baseline standard automated perimetry data." *Invest Ophthalmol Vis Sci*. 2009 Feb;50(2):674-80. PMID: 18936149.
70. Sultan MB, **Mansberger SL**, Lee PP. Understanding the importance of IOP variables in glaucoma: a systematic review. *Surv Ophthalmol*. 2009 Nov-Dec;54(6):643-62. PMID: 19665744..
71. McClure TM, Choi D, Becker T, Cioffi GA, **Mansberger SL**. The effect of visual impairment on vision-related quality of life in American Indian/Alaska Natives. *Ophthalmic Epidemiol*. 2009 Mar-Apr;16(2):128-35. PMID: 19353401.
72. Brandt J, Pham H, **Mansberger SL**. "Argon Laser Trabeculoplasty: Still the Gold Standard." *Surv Ophthalmol*. 2009 May-Jun;54(3):428. author reply.
73. Nguyen HT, Pikey KP, Gardiner SK, Gritz D, Krishnadas D, Cioffi GA, **Mansberger SL**. Intraobserver variability of confocal scanning laser ophthalmoscopy with and without stereo photographs. *Br J Ophthalmol*. 2009 Nov;93(11):1552-3. PMID: 19854740.
74. **Mansberger SL**. Are you compliant with addressing glaucoma adherence? *Am J Ophthalmol*. 2010 Jan;149(1):1-3. PMID: 20103035.
75. **Mansberger SL**. "Risk factors: The risk calculator" Book chapter. In: Giacony JA, Law SK, Coleman AL, Caprioli J, editors. *Pearls of glaucoma management*. Berlin: Springer; 2010. p. 191-194.
76. O'Leary N, Crabb DP, **Mansberger SL**, et al. Glaucomatous progression in series of stereoscopic photographs and Heidelberg retina tomograph images. *Arch Ophthalmol* 2010;128:560-8. PMID: 20457976.
77. **Mansberger SL**. "Use Risk Assessment when treating your ocular hypertension and glaucoma patients." Book Chapter. *Glaucoma Topics and Trends*. 2010: p5-6.
78. Weinreb RN, Zangwill LM, Jain Sonia, Becerra LM, Dirkes Keri, Piltz-Seymour JR, Cioffi GA, Trick GL, Coleman AL, Brandt JD, Liebmann JM, Gordon MO, Kass MA for the **OHTS CLSO Ancillary Study Group**. Predicting the Onset of Glaucoma: The Confocal Scanning Laser Ophthalmoscopy

- Ancillary Study to the Ocular Hypertension Treatment Study. *Ophthalmology* 2010; 117(9):1674-83. PMID:20633931.
79. Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT, Kass MA, for the **Ocular Hypertension Treatment Study Group**. The Utility of the Monocular Trial: Data from the Ocular Hypertension Treatment Study. *Ophthalmology* 2010;117(11):2047-54. PMID:20619460.
 80. Artes PH, Chauhan BC, Keltner JL, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA, for the **Ocular Hypertension Treatment Study Group**. Longitudinal and Cross-Sectional Analyses of Visual Field Progression in Participants of the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2010;128(12):1528-32. PMID:21149774.
 81. McClure TM, Wooten K, Nield C, Becker TM, **Mansberger SL**. The Impact of Eyeglasses on Vision-Related Quality of Life in American Indian/Alaska Natives. *Am J Ophthalmol*. 2011 Jan;151(1):175-182. PMID: 20951973.
 82. Gao F, Miller JP, Xiong C, Beiser JA, Gordon MO, the **Ocular Hypertension Treatment Study (OHTS) Group**. A Joint-Modeling Approach to Assess the Impact of Biomarker Variability on the Risk of Developing Clinical Outcome. *Statistical Methods & Applications*. 2011;20(1):83-100. PMID:21339862.
 83. Hoffelt Z, Fallon S, Wong BA, Lucas B, Coleman AL, Mills RP, Wilson R, **Mansberger SL**. Glaucoma public service announcements: factors associated with follow-up of participants with risk factors for glaucoma. *Ophthalmology*. Jul;118(7):1327-33. 2011. PMID: 21439644
 84. Dreer LE, Girkin C, **Mansberger SL**. Determinants of Medication Adherence to Topical Glaucoma Therapy. *Journal of Glaucoma*. 2012 Apr-May;21(4):234-40. PMID:21623223
 85. De Moraes CG, Demirel S, BScOptom, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA, for the **Ocular Hypertension Treatment Study Group**. Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2012;130:1541-46. PMID: 22892940.
 86. Thapa SS, Paudyal I, Khanal S, Paudel N, **Mansberger SL**, van Rens GH. Central corneal thickness and intraocular pressure in a Nepalese population: the Bhaktapur Glaucoma Study. *J Glaucoma*. 2012 Sep;21(7):481-5. PMID: 21499121.
 87. **Mansberger SL**, MacKenzie PJ, Falardeau J. Optic disc cupping associated with neurosyphilis. *J Glaucoma*. 2013 Feb;22(2):80-3. PMID: 21946555.
 88. **Mansberger SL**, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA; Ocular Hypertension Treatment Study Group. Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. *Ophthalmology*. 2012 Sep;119(9):1826-31. PMID: 22608478.
 89. Gardiner SK, Demirel S, De Moraes CG, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA; **Ocular Hypertension Treatment Study Group**. Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study. *Invest Ophthalmol Vis Sci*. 2013 Feb;54(2):1252-9. PMID 23349433.
 90. Lloyd MJ, **Mansberger SL**, Fortune BA, Nguyen H, Torres R, Demirel S, Gardiner SK, Johnson CA, Cioffi GA. Features of optic disc progression in patients with ocular hypertension and early glaucoma. *J Glaucoma*. 2013 Jun-Jul;22(5):343-8. PMID: 23719180.
 91. Koenigsman H, **Mansberger SL**. Choroidal Effusions. Book Chapter in *Glaucoma: Medical Diagnosis and Therapy*. Editors: Shaarawy, Sherwood, Hitchings, Crowston. Elsevier Saunders. ISBN: 978-0-7020-5193-7. 2015
 92. **Mansberger SL**. "Cataract surgery: The 'New' glaucoma procedure" Book Chapter in *Surgical Innovations in Glaucoma*. Editors: Samples and Ahmed. Springer. ISBN-13: 978-1461483472 ISBN-10: 1461483476. 2014
 93. **Mansberger SL**, Gleitsmann K, Gardiner S, Sheppler C, Demirel S, Wooten K, Becker TM. Comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic retinopathy screening examinations: a randomized controlled trial. *Telemed J E Health*. 2013 Dec;19(12):942-8. PMID: 24102102

94. **Mansberger SL**, Sheppler CR, McClure TM, Vanalstine CL, Swanson IL, Stoumbos Z, Lambert WE. Psychometrics of a new questionnaire to assess glaucoma adherence: the Glaucoma Treatment Compliance Assessment Tool (an American Ophthalmological Society thesis). *Trans Am Ophthalmol Soc.* 2013 Sep;111:1-16. PMID: 24072942
95. Zangwill LM, Jain S, Dirkes K, He F, Medeiros FA, Trick GL, Brandt JD, Cioffi GA, Coleman AL, Liebmann JM, Piltz-Seymour JR, Gordon MO, Kass MA, Weinreb RN for the **Ocular Hypertension Treatment Study Group**. Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. The Rate of Structural Change: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Am J Ophthalmology* 2013;155(6):971–82. PMID: 23497845.
96. Gardiner SK, Demirel S, Gordon MO, Kass MA, for the **Ocular Hypertension Treatment Study Group**. Seasonal Changes in Visual Field Sensitivity and Intraocular Pressure in the Ocular Hypertension Treatment Study. *Ophthalmology* 2013 Apr;120(4):724-30. PMID: 23357622. PMCID: PMC3618610.
97. Sheppler, CR, Lambert, WE, Gardiner, SK, Becker, TM, **Mansberger, SL**. Predicting Adherence to Diabetic Eye Exams: Development of the Compliance with Annual Diabetic Eye Exams Survey. *Ophthalmology* 2014 Jun;121(6):1212-9. PMID: 24518614
98. SK Gardiner, WH Swanson, D Goren, **SL Mansberger**, S Demirel. Assessment of the reliability of standard automated perimetry in regions of glaucomatous damage. *Ophthalmology*. 2014 Jul;121(7):1359-69. PMID: 24629617
99. Kinast RM, Barker GT, Day SH, Gardiner SK, **Mansberger SL**. Factors Related to Online Patient Satisfaction with Ophthalmologists. *Ophthalmology*. 2014 Sep;121(9):1843-5 PMID: 24856505
100. Estrovich I and **Mansberger SL**. "Does cataract extraction produce a significant and sustained IOP reduction? When should I perform a combined procedure versus cataract surgery alone?" *Curbside Consultation in Glaucoma: 49 Clinical Questions*, second edition. Editors: Heuer, Lewis, Panarelli, and Gedde. Slack Incorporated. ISBN 978-1-61711-639-1. 2015
101. Cook, P. F., Schmiege, S. J., **Mansberger, S.**, Kammer, J., Fitzgerald, T., & Kahook, M. Y. Predictors of adherence to glaucoma treatment in a multisite study. *Annals of Behavioral Medicine*. *Ann Behav Med.* 2015 Feb;49(1):29-39. PMID: 25248302
102. **Mansberger SL**. "Risk factors: The risk calculator" Book chapter. In: Giaconi JA, Law SK, Coleman AL, Caprioli J, editors. *Pearls of glaucoma management*. (Accepted, in Press 2015).
103. Boey PY, **Mansberger SL**. Ocular Hypertension: an approach to assessment and management. *Can J Ophthalmology*. 2014 Dec;49(6): 489-96.
104. Savatovsky E, Mwanza JC, Budenz DL, Feuer WJ, Vandenbroucke R, Schiffman JC, Anderson DR; **Ocular Hypertension Treatment Study**. Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment. *Ophthalmology*. 2015 Jan;122(1):79-86. PMID: 25208858
105. **Mansberger SL**, Sheppler C, Barker G, Gardiner SK, Demirel S, Wooten K, Becker TM. Long-term Comparative Effectiveness of Telemedicine in Providing Diabetic Retinopathy Screening Examinations: A Randomized Controlled Trial. *JAMA Ophthalmol.* 2015 May;133(5):518-25. PMID: 25741666
106. Estrovich IE, Shen C, Chu Y, Downs JC, Gardiner S, Straiko M, **Mansberger SL**. Schiottz tonometry accurately measures intraocular pressure in Boston type 1 keratoprosthesis eyes. *Cornea*. 2015. Jun;34(6):682-5. PMID: 25782403
107. Gardiner SK, Demirel S, Goren D, **Mansberger SL**, Swanson W. The Effect of Stimulus Size on the Reliable Stimulus Range of Perimetry. *Translational Vision Science and Technology*. 2015. Mar 27;4(2):10. PMID: 25883877
108. GT Barker, PF Cook, SJ Schmiege, MY Kahook, JA Kammer, **SL Mansberger**. Psychometric properties of the Glaucoma Treatment Compliance Assessment Tool in a Multicenter Trial. *American Journal of Ophthalmology*. 2015 Jun;159(6):1092-1099. PMID: 25794793

109. LJ Kopplin, **SL Mansberger**. Predictive Value of Screening Tests for Visually Significant Eye Disease. *American Journal of Ophthalmology*. 2015 Sep;160(3):538-546. PMID: 26052087
110. RM Kinast, K Akula, AE DeBarber, GT Barker, SK Gardiner, E Whitson, **SL Mansberger**. The Degradation of Mitomycin C Under Various Storage Methods. *Journal of Glaucoma*. 2015 May 14. [Epub ahead of print] PMID: 26020687
111. Teleretinal screening for diabetic retinopathy--reply. **Mansberger SL**. *JAMA Ophthalmol*. 2015 Oct;133(10):1222. PMID: 26334990
112. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern(®) Guidelines. Prum BE Jr, Lim MC, **Mansberger SL**, Stein JD, Moroi SE, Gedde SJ, Herndon LW Jr, Rosenberg LF, Williams RD. *Ophthalmology*. 2016 Jan;123(1):P112-51. PMID: 26581560
113. Primary Angle Closure Preferred Practice Pattern(®) Guidelines. Prum BE Jr, Herndon LW Jr, Moroi SE, **Mansberger SL**, Stein JD, Lim MC, Rosenberg LF, Gedde SJ, Williams RD. *Ophthalmology*. 2016 Jan;123(1):P1-P40. PMID: 26581557.
114. Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines. Prum BE Jr, Rosenberg LF, Gedde SJ, **Mansberger SL**, Stein JD, Moroi SE, Herndon LW Jr, Lim MC, Williams RD. *Ophthalmology*. 2016 Jan;123(1):P41-P111. PMID: 26581556
115. Putting the "Metal" Back in Meta-Analysis. Vanner EA, **Mansberger SL**. *Am J Ophthalmol*. 2015 Nov;160(5):849-50. PMID: 26354732RM
116. Concentration Accuracy of Compounded Mitomycin C for Ophthalmic Surgery. Kinast RM, Akula KK, **Mansberger SL**, Barker GT, Gardiner SK, Whitson E, DeBarber AE. *JAMA Ophthalmol*. 2015 Dec 10:1-5. PMID: 26661632.
117. Savatovsky E, Mwanza JC, Budenz DL, Feuer WJ, Vandenbroucke R, Schiffman JC, Anderson DR for the **Ocular Hypertension Treatment Study Group**; Ocular Hypertension Treatment Study Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment. *Ophthalmology* 2015 Jan;122(1):79-86. PMID: 25208858.
118. Christopher M, Abramoff MD, Tang L, Gordon MO, Kass MA, Budenz DL, Fingert JH, Scheetz TE for the **Ocular Hypertension Treatment Study Group**. Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension.. *Invest Ophthalmol Vis Sci*. 2015 Jul 1;56(8):4470-9. PMID: 26193923. PMCID: PMC4509059.
119. Feng Gao, J Philip Miller, Julia A Beiser, Chengjie Xiong, Mae O Gordon, for the **Ocular Hypertension Treatment Study Group**. Predicting Clinical Binary Outcome Using Multivariate Longitudinal Data: Application to Patients with Newly Diagnosed Primary Open - Angle Glaucoma. *J Biom Biostat* 6:254. PMID: 26904374. PMCID: PMC4760987.
120. Vision-related Quality of Life in Glaucoma Suspect or Early Glaucoma Patients. Alqudah A, **Mansberger SL**, Gardiner SK, Demirel S. *J Glaucoma*. 2016 Aug;25(8):629-33. PMID: 27483331
121. Motivational Interviewing or Reminders for Glaucoma Medication Adherence? Results of a Multi-Site Randomized Controlled Trial. Cook PF, Schmiede SJ, **Mansberger SL**, Shepler C, Kammer J, Fitzgerald T, Kahook MY. *Psychol Health*. 2016 Oct 4:1-39. PMID: 27701902
122. Eye disease in patients with diabetes screened with telemedicine. Park DW, **Mansberger SL**. *Telemed J E Health*. 2017 Feb;23(2):113-118. PMID: 27328169
123. Effect of restricting perimetry testing algorithms to reliable sensitivities on test-retest variability. Gardiner S, **Mansberger SL**. *Invest Ophthalmol Vis Sci*. 2016 Oct 1;57(13):5631-5636. PMID: 27784065
124. Scheetz TE, Faga B, Ortega L, et al for the **Ocular Hypertension Treatment Study Group**. Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study. *Ophthalmology* 2016;123(12):2527-36. PMID: 27707548. PMCID: PMC5121091.
125. Automated segmentation errors when using optical coherence tomography to measure retinal nerve fiber layer thickness in glaucoma. **Mansberger SL**, Menda S, Gardiner SK, Fortune BF, Demirel S. *Am J Ophthalmol*. 2017 Feb;174:1-8. PMID: 27818206.
126. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial. Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, Lee SS, Goodkin

- ML, Zhang J, Whitcup SM, Robinson MR; **Bimatoprost SR Study Group**. Am J Ophthalmol. 2017. 2017 Mar;175:137-147. PMID: 28012819
127. Budenz DL, Huecker JB, Gedde SJ, Gordon M, Kass M for the **Ocular Hypertension Treatment Study Group**. Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. Am J Ophthalmol. Feb 2017;174:126-133. PMID: 27832941.
128. [Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial](#). Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, Lee SS, Goodkin ML, Zhang J, Whitcup SM, Robinson MR; **Bimatoprost SR Study Group**. Am J Ophthalmol. 2017 Mar;175:137-147. doi: 10.1016/j.ajo.2016.11.020. Epub 2016 Dec 22. PMID: 28012819
129. MOC: Making Ophthalmologists Crazy or Maintenance of Certification? **Mansberger SL**. Glaucoma Today. 2017. <http://glaucomatoday.com/2017/02/making-ophthalmologists-crazy-or-maintenance-of-certification/>.
130. Detection of functional change using cluster trend analysis in glaucoma. Gardiner S, **Mansberger SL**, Demirel SA. Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO180-BIO190. doi: 10.1167/iovs.17-21562. PMID: 28715580
131. Psychometric Properties of the Glaucoma Treatment Compliance Assessment Tool (GTCAT) in a Brazilian population. RY Abe, LC Wen, GT Barker, **SL Mansberger**. J Glaucoma. 2018. Mar;27(3):257-265. PMID: 29369851
132. Peripapillary retinoschisis in glaucoma: association with progression and OCT signs of Muller cell involvement. Fortune B, Ma KN, Gardine SK, Demirel S, **Mansberger SL**. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2818-2827. doi: 10.1167/iovs.18-24160. PMID: 29860466
133. Glaucoma Specialist Optic Disc Margin, Rim Margin and Rim Width Discordance in Glaucoma and Glaucoma Suspect Eyes. American Journal of Ophthalmology. Hong SW, Koenigsman H, Ren Ruojin, Yang H; Gardiner SK, Reynaud J, Kinast RM, **Mansberger SL**, Fortune B, Demirel S, Burgoyne CF. Am J Ophthalmol. Aug;192:65-76. PMID: 29750947
134. Glaucoma Adherence - from therapy to the future. R Kinast and **SL Mansberger**. American Journal of Ophthalmology. Am J Ophthalmol. 2018 Jul;191:xiii-xv. doi: 10.1016/j.ajo.2018.04.002. Epub 2018 Apr 30. No abstract available. PMID: 29716719
135. Psychometric Properties of the Reduced Version of the Glaucoma Treatment Compliance Assessment Tool (GTCAT). Barker GT and **Mansberger SL**. Ophthalm Epidemiology. Ophthalmic Epidemiol. 2019 Feb;26(1):55-62. doi: 10.1080/09286586.2018.1516785. Epub 2018 Sep 11. PMID: 30204034
136. Characteristics of Patients Receiving Treatment Who Deny A Diagnosis Glaucoma or Elevated Intraocular Pressure in the United States. Lowry EA, **Mansberger SL**. J Glaucoma. 2018 Nov;27(11):1029-1031. doi: 10.1097/IJG.0000000000001035. PMID: 30059410.
137. Optical coherence tomography segmentation errors of the retinal nerve fiber layer persist over time. N. Nagarkatti-Gude, S.K. Gardiner, B Fortune, S Demirel, **SL Mansberger**. J Glaucoma. J Glaucoma. 2019 May;28(5):368-374. doi: 10.1097/IJG.0000000000001222. PMID: 30855415
138. Glaucoma Specialist Detection of Optical Coherence Tomography Suspicious Rim Tissue in Glaucoma and Glaucoma Suspect Eyes. Hong SW, Koenigsman H, Yang H, Ren R, Reynaud J, Kinast RM, **Mansberger SL**, Fortune B, Demirel S, Gardiner SK, Burgoyne CF. Am J Ophthalmol. 2019 Mar;199:28-43. doi: 10.1016/j.ajo.2018.10.027. Epub 2018 Nov 7. PMID: 30414397
139. Risk Factors for Adherence to Annual Dilated Eye Examinations Among US Patients with Diagnosed Diabetes. SE Eppley, **SL Mansberger**, S Ramanathan, EA Lowry. Ophthalmology. 2019 Nov;126(11):1492-1499. doi: 10.1016/j.ophtha.2019.05.033. Epub 2019 Jun 15. PMID: 31281055.
140. [Obstructive Sleep Apnea and Primary Open-angle Glaucoma](#). Sanders DS, **Mansberger SL**. J Glaucoma. 2019 Aug;28(8):667. doi: 10.1097/IJG.0000000000001304. No abstract available. PMID: 31188230
141. Effect of Trabeculectomy on Optical Coherence Tomography (OCT) Measurements of the Optic Nerve Head Neuroretinal Rim Tissue. FS Sanchez, DS Sanders, JJ Moon, SK Gardiner, J Reynaud,

- B Fortune, **SL Mansberger**. *Ophthalmol Glaucoma*. 2020 Jan-Feb;3(1):32-39. doi: 10.1016/j.ogla.2019.09.003. Epub 2019 Oct 4. PMID: 32632405
142. OCT Structural Abnormality Detection in Glaucoma using Topographically Correspondent Rim and Retinal Nerve Fiber Layer Criteria. Hongli Yang, Haomin Luo, Christy Hardin, Ya Xing Wang, Jin Wook Jeoung, Cindy Albert, Jayme R Vianna, Glen P. Sharpe, Juan Reynaud, Shaban Demirel, **Steven L. Mansberger**, Brad Fortune, Marcelo Nicolela, Stuart K Gardiner, Balwantray C. Chauhan, and Claude F. Burgoyne, MD. 2019. Accepted in Press. *American Journal of Ophthalmology*.
143. [24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant \(Bimatoprost SR\) in Glaucoma Patients](#). Craven ER, Walters T, Christie WC, Day DG, Lewis RA, Goodkin ML, Chen M, Wangsadipura V, Robinson MR, Bejanian M; **Bimatoprost SR Study Group**. *Drugs*. 2020 Feb;80(2):167-179. doi: 10.1007/s40265-019-01248-0. PMID: 31884564
144. Predicting adherence with the Glaucoma Treatment Compliance Assessment Tool. Sanchez F, **Mansberger SL**, Newman-Casey PL. *J Glaucoma*. 2020 Nov;29(11):1017-1024. doi: 10.1097/IJG.0000000000001616. PMID: 32740508
145. "Detection of functional deterioration in glaucoma by trend analysis using overlapping clusters of locations". SK Gardiner and **SL Mansberger**. *Trans. Vis. Sci. Tech.*. 2020;9(9):12. PMID: 32879768
146. Detection of functional deterioration in glaucoma by trend analysis using comprehensive overlapping clusters of locations. SK Gardiner and **SL Mansberger**. *Sci Rep*. 2020 Oct 28;10(1):18470. doi: 10.1038/s41598-020-75619-z. PMID: 33116229
147. Time lag between functional change and loss of retinal nerve fiber layer in glaucoma. Gardiner SK, **Mansberger SL**, Fortune B. *Invest Ophthalmol Vis Sci*. 2020 Nov 2;61(13):5. doi: 10.1167/iovs.61.13.5. PMID: 33141891
148. Association of optic nerve head prelaminar schisis with glaucoma. Lowry EA, **Mansberger SL**, Gardiner SK, Yang H, Sanchez F, Reynaud J, Demirel S, Burgoyne CF, Fortune B. Accepted In Press. *Am J Ophthalmol*. 2021 Mar;223:246-258. doi: 10.1016/j.ajo.2020.10.021. Epub 2020 Nov 6. PMID: 33166501
149. Novel Eye Drop Delivery Aid Improves Outcomes and Satisfaction. Sanchez FG, **Mansberger SL**, Kung Y, Gardiner SK, Burgoyne CF, Cunningham ET Jr, Rees JP, Jones EP, Kinast RM. *Ophthalmol Glaucoma*. 2021 Jan 12:S2589-4196(21)00011-9. doi: 10.1016/j.ogla.2021.01.001. Online ahead of print. PMID: 33444854
150. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern®. Gedde SJ, Lind JT, Wright MM, Chen PP, Muir KW, Vinod K, Li T, **Mansberger SL**; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. *Ophthalmology*. 2021 Jan;128(1):P151-P192. doi: 10.1016/j.ophtha.2020.10.023. Epub 2020 Nov 12. PMID: 33189698 No abstract available.
151. Primary Angle-Closure Disease Preferred Practice Pattern®. Gedde SJ, Chen PP, Muir KW, Vinod K, Lind JT, Wright MM, Li T, **Mansberger SL**; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. *Ophthalmology*. 2021 Jan;128(1):P30-P70. doi: 10.1016/j.ophtha.2020.10.021. Epub 2020 Nov 12. PMID: 33189697
152. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, Li T, **Mansberger SL**; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. *Ophthalmology*. 2021 Jan;128(1):P71-P150. doi: 10.1016/j.ophtha.2020.10.022. Epub 2020 Nov 12. PMID: 33189695
153. Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up. Kass MA, Heuer DK, Higginbotham EJ, Parrish RK, Khanna CL, Brandt JD, Soltau JB, Johnson CA, Keltner JL, Huecker JB, Wilson BS, Liu L, Miller JP, Quigley HA, Gordon MO; **Ocular Hypertension Study Group**. *JAMA Ophthalmol*. 2021 Apr 15;139(5):1-9. PMID: 33856434
154. Cataract Surgery Lowers Intraocular Pressure and Medication Use in the Treatment Group in the Ocular Hypertension Treatment Study (OHTS). **SL Mansberger**, SK Gardiner, M Gordon, M Kass, P Rumulu. *American Journal of Ophthalmology*. 2022 Apr;236:53-62. doi: 10.1016/j.ajo.2021.07.008. Epub 2021 Jul 17. PMID: 34280363

155. Adherence with Glaucoma Medications: Barriers to Success and Prospects for Improvement. Michael Gale, Robert M Kinast, Facundo G Sanchez, **Steven L Mansberger**. *Current Ophthalmology Reports* (2021) 9:184–189. <https://doi.org/10.1007/s40135-021-00273-1>
156. BY Hong and **SL Mansberger**. “Choroidal Effusion”. Book Chapter. “Glaucoma” with editors Shaarawy, Crowston, and Sherwood. Elsevier. 2021.
157. CL McNiel, FG Sanchez, JP Rees, SK Gardiner, JW Young, RM Kinast, Amber Young, EP Jones, **SL Mansberger**. Intraocular pressure and medication burden with cataract surgery alone, or cataract surgery combined with trabecular bypass or goniotomy. *J Glaucoma*. 2022 Jun 1;31(6):423-429. doi: 10.1097/IJG.0000000000002028. Epub 2022 Mar 29. PMID: 35353775
158. Gardiner SK, Kinast RM, Chen TC, Strouthidis NG, De Moraes CG, Nouri-Mahdavi K, Myers JS, Jeoung JW, Lind JT, Rhodes LA, Budenz DL, **Mansberger SL**. Clinicians' Use of Quantitative Information When Assessing the Rate of Structural Progression in Glaucoma. *Ophthalmol Glaucoma*. 2022. PMID: 35144008
159. Gardiner SK, Kinast RM, De Moraes CG, Budenz DL, Jeoung JW, Lind JT, Myers JS, Nouri-Mahdavi K, Rhodes LA, Strouthidis NG, Chen TC, **Mansberger SL**. Clinicians' Use of Quantitative Information when Assessing the Rate of Functional Progression in Glaucoma. *Ophthalmol Glaucoma*. 2022. PMID: 35288335.
160. Feldman RM, Chuang AZ, **Mansberger SL**, Tanna AP, Blieden LS, Bell NP, Gross RL, Pasquale LR, Greenfield DS, Liebmann JM, Weinreb RN; ASSISTS Group. Outcomes of the Second Aqueous Shunt Implant Versus Transscleral Cyclophotocoagulation Treatment Study: A Randomized Comparative Trial. *J Glaucoma*. 2022 Jul 21. PMID: 35901309.
161. FG Sanchez, SK Gardiner, S Demirel, JP Rees, **SL Mansberger**. Geospatial analysis of blindness within rural and urban counties. *PLoS One*. 2022 Oct 10;17(10):e0275807. doi: 10.1371/journal.pone.0275807. eCollection 2022. PMID: 36215279
162. JX Ma, AZ Chuang, RM Feldman, **SL Mansberger**, AP Tanna, LS Blieden, D Shoham, NP Bell, RL Gross; LR Pasquale; DS Greenfield, JM Liebmann, RN Weinreb for the ASSISTS Group. Direct Costs of Second Aqueous Shunt Implant versus Transscleral Cyclophotocoagulation (The Assists Trial). *J Glaucoma*. 2023 Mar 1;32(3):145-150. doi: 10.1097/IJG.0000000000002143. Epub 2023 Feb 1. PMID: 36848258
163. Bennett Y. Hong, Brad Fortune, Robert M. Kinast, Claude F. Burgoyne, Jack P. Rees, **Steven L. Mansberger**. Optic nerve cavitations in glaucoma suspect and glaucoma patients. *Am J Ophthalmol Case Rep*. 2022 Oct 20;28:101733. doi: 10.1016/j.ajoc.2022.101733. eCollection 2022 Dec. PMID: 36345413
164. Robert M Kinast, Facundo G Sanchez, Jack P Rees, Kaileen Yeh, Stuart K Gardiner, Jacob Dawes, Matthew L. Johnston, J David Porter, Viridian Klei, **Steven L Mansberger**. Eye Drop Adherence with an Eye Drop Bottle Cap Monitor. *J Glaucoma*. 2023 May 1;32(5):369-373. doi: 10.1097/IJG.0000000000002166. Epub 2022 Dec 21. PMID: 37053080 Clinical Tria
165. Facundo G. Sanchez and **SL Mansberger**. Psychological Barriers and Innovations in Glaucoma Adherence. Book Chapter. In press
166. Grissom N, Gardiner SK, Rees JP, Sanchez FG, **Mansberger SL**, Cunningham ET Jr, Burgoyne CF, Rice K, Belter C, Kinast RM. Patients with Low Vision Struggle with Placing Eye Drops and Benefit from an Eye Drop Aid. *Ophthalmol Glaucoma*. 2023 Sep-Oct;6(5):501-508. doi: 10.1016/j.ogla.2023.04.004. Epub 2023 Apr 20. PMID: 37084868
167. Gardiner SK, **Mansberger SL**. Detectability of Visual Field Defects in Glaucoma Using Moving Versus Static Stimuli for Perimetry. *Transl Vis Sci Technol*. 2023 Aug 1;12(8):12. doi: 10.1167/tvst.12.8.12. PMID: 37578428
168. Oltramari, L., **Mansberger, S.L.**, Souza, J.M.P. *et al*. The association between glaucoma treatment adherence with disease progression and loss to follow-up. *Sci Rep* **14**, 2195 (2024). <https://doi.org/10.1038/s41598-024-52800-2>
169. Hongli Yang, PhD; Jack P. Rees; Facundo G. Sanchez, MD; Stuart K Gardiner, PhD; **Steven L. Mansberger MD, MPH**. Optical Coherence Tomography segmentation errors with Bruch’s

Membrane Opening-Minimum Rim Width as compared to Retinal Nerve Fiber Layer Thickness.
Accepted in press. Ophthalmology Glaucoma.

170. Fechtner R, **Mansberger SL**, Branch J, Mulaney J, Ziebell S, Lopez K, Hubatsch D. A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study. AJO 2024. In press.
171. Oltramari L, **Mansberger SL**, Souza JMP, de Souza LB, de Azevedo SFM, Abe RY. The association between glaucoma treatment adherence with disease progression and loss to follow-up. Sci Rep. 2024 Jan 25;14(1):2195. doi: 10.1038/s41598-024-52800-2. PMID: 38273029; PMCID: PMC10810888.

Hobbies/Interests

I enjoy sports, hiking, acoustic guitar, novels, traveling, gourmet food, and outside endeavors.

Family

Wife: Heather

Daughters: Katelynn, Allison, Louisa